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Abstract 
__________________________________________________________________________ 
 
 
Does the introduction of a parent reported outcome measure improve the self efficacy of 
caregivers of children with cystic fibrosis?  
 
 
Background: Parent Reported Outcome Measures (PROM) are an integral component of 
cystic fibrosis (CF) care yet there is little evidence supporting the role of PROM and their 
benefits.  We are conducting a single centre pilot study to assess the impact of a PROM on 
the Self Efficacy (SE) of caregivers of children with CF.  
Aims:  The aims of this study were to explore the feasibility and benefits of introducing the 
Challenges of Living with Cystic Fibrosis-Questionnaire (CLCF-Q) into clinical practice.  
The anticipated outcome was an increase in the SE of the caregivers. 
Methods: We are conducting a parallel randomised controlled intervention pilot study using 
the Cystic Fibrosis Self Efficacy-Questionnaire (CFSE-Q) as an outcome measure. All 
participants completed the CFSE-Q at 2 time points. Between these time points the 
intervention group completed the CLCF-Q as part of their annual assessment. They received 
feedback at their next clinic appointment from the team in the form of colour coded tables 
illustrating both the positive and negative issues raised in the CLCF-Q. They were invited to 
talk to members of the CF team and others (consultants, CF nurses, dieticians, 
physiotherapists, psychologists, pharmacists, family doctors and the school) about the issues 
raised in the CLCF-Q. Select participants (n=1) were also invited to participate in narrative 
interviews. 
Results: Preliminary data from 18 cases; of children aged 5-13 years (11♂, 7♀) are 
reported, (8 control, 10 intervention).  The SE score ranged from 26/40 to 35/40 at baseline. 
In the control group the SE score remained relatively static whilst the intervention group has 
shown an increase in SE.  Baseline SE ranged from 26/40 – 39/40 using only validated items 
and 36/56 – 53/56 including non-validated items.  Average change in SE was -0.1 in the 
control group and 1.3 in the intervention group.  With the inclusion of the non-validated 
items, average increase in SE was 0.8 in the control group and 4.2 in the intervention group.   
The control group showed consistent improvement in 4 items and a decline in 3 items.  In 
comparison the intervention group showed consistent improvement in 8 items and decline in 
only 1 item.   
Conclusions: The CF team play a significant role in the lives of families of children with CF.  
They are recognised as invaluable by caregivers and are the first port of call when faced 
with a challenge. Potentially, the PROM CLCF-Q may have an important role in the annual 
assessment process. As well as extracting clinical data it raises unidentified concerns which 
may alert the CF team to otherwise un-recognised issues. A favourable consequence of 
routinely introducing the CLCF-Q into the annual assessment process may be an increase in 
the caregiver’s SE through improved communication between the caregiver and the CF 
team. 
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Preface 
 
__________________________________________________________________________ 
 
“It is no sin to devise oversimplified working concepts of nature’s secrets.  The scientific 
sinning comes with refusal to complicate such concepts to the degree dictated by irrefutable 
data or to discard them completely should they become untendable1.”  
- Anonymous 
 
Chronic illness affects patients and their caregivers in many ways both physically and 
mentally.  Unfortunately the majority of medicine aims to fulfil the needs of only one.  This 
study concentrates on the other area which is frequently overlooked. 
 
Over the last seven decades the management of cystic fibrosis has changed dramatically.  
Cystic fibrosis has progressed from a fatal childhood disease to a multisystem adult disease 
requiring multidisciplinary involvement.  Over this period of change, the quality of life of 
patients and their caregivers has come under scrutiny.  Consequently, increasing time and 
effort has been invested into the careful examination of their quality of life.  Decreasing the 
burden of care and improving the quality of life of the caregivers and families was pivotal to 
this movement and is the focus of this study. 
 
Employing quantitative and qualitative methods this study looks at the stress that the burden 
of caring for a child with cystic fibrosis brings to a family.  Families of chronically ill 
children face challenges on a daily basis which are entirely foreign to the normal population.  
This project concentrates on the affect of these challenges on the caregivers of children with 
cystic fibrosis.  It explores possible interventions which could ease burden. 
 
The role of the caregiver is crucial to the well-being of the patient, particularly in paediatrics.  
Self efficacy was a term coined by Albert Bandura in 1977.  It refers to one’s belief in one’s 
own ability to complete any given task.  For caregivers of children with cystic fibrosis 
maintaining a good level of self efficacy may be important.  Any change in self efficacy 
could affect the caregiver’s management of their child’s disease. 
 
This study asks if it possible to improve the self efficacy of the caregiver.  A recently 
developed and validated burden of care measure; the Challenges of Living with Cystic 
xii 
 
Fibrosis-Questionnaire and a series of feedback tools were used to determine their role in 
improving the self efficacy of the caregiver and subsequently improving the care of the child 
with cystic fibrosis. 
. 
Latifa Patel 
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Chapter One 
Introduction 
_____________________________________________________________________ 
 
“Understanding the life experiences of family members caring for a child with cystic fibrosis 
will provide the empiric underpinnings for appropriate clinical interventions2.”   
- Carpenter et al, 2004 
 
2 
 
 
This thesis builds on the theory discussed by Glasscoe et al introducing the Challenges of 
Living with Cystic Fibrosis-Questionnaire (CLCF-Q) as an intervention3.  The effect, of 
introducing this Parent Reported Outcome Measure (PROM) into clinical practice, on the 
caregiver’s Self Efficacy (SE) is mapped and supported by qualitative data. 
 
Chapter 1 outlines the history of Cystic Fibrosis (CF) and details the major developmental 
milestones in the diagnosis and management of CF.  Chapter 2 describes the findings of the 
literature review outlining the role of PROM in the measurement of a patient’s Quality of 
Life (QOL).  The concept of self efficacy and its relatively novel role in the management of 
children with CF is detailed; more specifically the role of assessing SE in caregivers. 
 
The latter half of the thesis concentrates on the methods applied.  The mixed methodology 
approach and the formation of the tools used are explained in detail in Chapter 3.  Chapter 4 
describes the preliminary raw results observed in the study.  Chapter 5 concludes the thesis 
bringing together the background knowledge, the original hypothesis and deducing a 
conclusion from the preliminary qualitative and quantitative results.
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History of Cystic Fibrosis 
 
_______________________________________________________________________ 
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1.1. Discovering Cystic Fibrosis 
 
“Woe to that child which kissed on the forehead tastes salty. He is bewitched and will soon 
die4.” 
- Anonymous 
This North European folklore originated between the 17th and 18th century.  It was believed 
to have described the fate of children who had inherited the previously fatal disease now 
known as CF4.  “Swollen, hardened, gleaming white pancreas,” is an extract describing the 
product of CF.  It was written in 1595 by Professor Peter Pauw from Lieden and describes 
the pancreas of a girl believed to be bewitched5.  This was not an isolated case. Over the 
years hundreds of documented findings have been uncovered, all describing the 
characteristics of typical CF.  Works of the late Rochholz, Rokitansky and Landsteiner in the 
early nineteenth century resemble examples of the complications of CF; malabsorption, 
pancreatic insufficiency and meconium ileus5-6. 
The aetiology of the similarly manifesting celiac disease, was unknown until 19507.  Prior to 
this discovery, it was largely associated with the symptoms of CF.  An account dated 1888, 
written by Samuel Gee, describes severely malnourished infants with the classical features of 
CF; failure to thrive, distended abdomen, intermittent diarrhoea, pale stools and histological 
changes to both the lungs and the pancreas5 8.  These cases were misdiagnosed as celiac 
disease.  
Prior to 1938, a cornerstone in the history of CF, a diagnosis of lone CF was rare and poorly 
understood.  Whilst Margaret Harper in Sydney described pancreatic abnormalities of 14 
children both clinically and at post mortem; which she believed were consistent with those of 
CF9-10, Americans Blackfan and Wolbach studying the effects of vitamin A deficiency 
discovered histological changes in the pancreases of 11 children5 11.  Following several post 
mortems on malnourished children, CF was differentially recognised from celiac disease.  It 
was the collective work of a number of clinicians around the world which resulted in the 
recognition of CF as lone disease6 12.  
Further reports revealed thick, sticky mucus clogging the ducts of many mucus glands in the 
body.  This arose to the term ‘mucoviscidosis,’13.  It was construed that the disease was a 
result of a genetic abnormality giving rise to pancreatic damage causing a lack of pancreatic 
enzymes.  Disease manifestations were believed to be a result of the consequent 
malabsorption.  This led to growth failure.  Poor nutritional status was assumed to be the 
cause of unusually high susceptibility to pulmonary infections.  Respiratory failure was the 
primary cause of death in young patients. Whilst, ‘cystic fibrosis of the pancreas,’ was 
5 
 
widely recognised it remained referred to as, ‘generalised exocrinopathy,’ due to the extent 
of exocrine glands involvement5-6.  Blackfan and May later documented similar pancreatic 
changes in 35 infants who also carried chronic lung infections5.  Similarly, Fanconi 
described recently manifesting lung histology in children whom he believed had suffered 
from celiac disease5.   
Pathologist Dorothy Anderson of Babies’ and Children’s Hospital, Columbia Presbyterian 
Medical Centre, New York laid another cornerstone with her work in 1938 when she 
published, ‘Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and 
pathological study12.’  Though she initially aimed to evaluate the clinical, laboratory and 
histological findings of children with celiac disease, her work amalgamated the works of 
others identifying a definite link between, ‘celiac disease,’ intestinal obstruction, intestinal 
and respiratory complications and the prominent pancreatic histology12.  A colleague of 
Andersen’s Paul di Sant’Agnese made a promising discovery in 1948.  During a heat wave 
in New York he discovered that many infants presenting with exhaustion were diagnosed 
with CF14.  This led to the discovery of an abnormality in their sweat.  He later found a 5-
fold increase in both sodium and chloride concentrations14.  Where it was previously thought 
that the fault was in the mucus production it now emerged that this was not the case.  
Furthermore this discovery made way for the diagnostic sweat test we now use.  This was 
closely followed by the recognition of the familial incidence of CF.  CF portrayed a 
Mendelian recessive inheritance pattern and it was now widely accepted that CF was a 
multisystem disease affecting organs other than the pancreas7 14. 
In 1983 Paul Quinton identified chloride transport as defect in CF using sweat ducts15.  
Knowles and Boucher also recognised an increased level of sodium reabsorption in the 
airways16-17.  And in 1989 Knowles et al found that the Nasal Potential Difference (NPD) 
was also abnormal in patients with CF.  CF patients had abnormalities concerning both 
sodium and chloride16.  They experienced increased sodium reabsorption and decreased 
chloride secretion.  Since this finding NPD measuring moved from a research tool to a 
crucial diagnosing tool.  The use of cells from sweat ducts remained a common trend and it 
was use of these in 1989 that changed the management of CF completely18.   
In 1989 the CF gene was isolated by positional cloning18-20.  It was the first gene to be 
identified by positional cloning whose use was previously completely unknown.  It was 
discovered almost simultaneously by two parties; Lap-Chee Tsui and Jack Riordan (Hospital 
for Sick Children, Toronto) and Francis Collins (University of Michigan)18-20.  The gene sat 
on chromosome 7 and at 250 kb in length coded for a protein of 1480 amino acids; the 
Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene21,22.  Over the last 
6 
 
century the management of CF had evolved with great pace and by the late twentieth century 
the disease was very well understood and controlled with the prognosis nearing the age of 50 
years.   
 
1.2. The Changing Methods of Diagnosing Cystic Fibrosis 
 
In the early twentieth century the diagnosis of CF was entirely pathological.  By 1948, 
elevated sodium chloride concentrations were recognised as a symptom of CF and the 
diagnosis moved to a fixed criterion; an elevation of greater than 60m/L and a sibling or first 
cousin with a diagnosis of CF.  This was however overruled by significant lung or pancreatic 
disease.  In practice the sweat test yielded difficult results and had to be carried out by 
allocated centres meeting national standards6 14.  Performed by experienced technicians it 
was common practice to repeat tests twice.  A percentage of CF patients did have normal 
sweat chloride concentrations and for these patients other tests were available.   Measuring 
NPD was first advised in 198916. 
Later in the same year, the gold standard for diagnosing CF stemmed from the identification 
of 2 CF mutations of 2 alleles19.  By the 21st century there were over 1600 identified CF 
mutations though 93% of patients were identified when tested for just 86 of these22.  Genetic 
screening fast became important and was now offered at the prenatal stage when parents 
were known carriers.  This was carried out using amniocentesis and chronic villous 
sampling23.   
The introduction of newborn screening in the United Kingdom (UK) in 2004 led to an 
increase of cases being diagnosed post-natally24.  All newborn babies in the UK were 
screened for phenylketonuria, congenital hypothyroidism, sickle cell disorders, medium 
chain acly-CoA dehydrogenase deficiency and CF.  This was known as the Guthrie test.  The 
level of Immunoreactive Trypsin (IRT) was measured in a blood spot collected at birth24.  
IRT was raised in most CF patients.  Unfortunately, the Guthrie test for CF yielded a high 
number of false positives (up to 5- times) and was followed by a repeat IRT level, sweat 
testing or genetic testing25.  In men, it was possible to check for sperm in the semen.  Late 
manifestations included intestinal obstruction and liver and gall bladder function25. 
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Figure 1.1: Milestones in the development of diagnosing, managing and treating cystic fibrosis6. 
 
 
 
1.3. The Significant Developments in Managing Cystic Fibrosis 
 
Early treatment of CF centred mainly round palliation. It wasn’t until the mid twentieth 
century that rudiment self assembled CF centres developed5.  Knowledge of the disease 
remained primitive with little awareness of the true causes of CF.  In 1954, Leroy Matthews 
in Cleveland centred his approach to treatment on 4 main concepts; respiratory relief, 
maintaining nutrition, antibiotic therapy and suppression of inflammation6.  He addressed 
each of the issues individually with aggressive treatment.  The results were a clear increase 
in survival rate.  The Cystic Fibrosis Foundation (CFF) was formed the following year.  This 
was a true milestone providing an excellent base for international communication and 
distribution of research findings.  It enabled resources and evidence-based research to be 
shared amongst centres further improving treatment.  The improvement in the treatment, 
management and survival of CF patients continued5.   
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1.3.1. The Four Main Concepts in Managing Cystic Fibrosis 
 
1.3.1.1. Respiratory Relief 
 
Though presently recognised as an independent component of CF resulting from a genetic 
mutation, lung disease was s initially believed to be the result of severe malnutrition5 26.  Post 
mortems revealed that the lungs of newborns carrying the CF genotype were normal unlike 
the digestive tract and pancreas which were affected at birth.  The only abnormality the lungs 
portrayed prior to infection is that of widening of the mouths of the submucosal glands26.  
Aims of early treatment were to clear the thick, mucous secretions that often plugged the 
airways.  This involved humidification, postural drainage and clapping.  Later, as novel 
methods were founded the focus moved to biological products; recombinant 
deoxyribonuclease (DNAse), polymersised actin and mucins in aid of improving pulmonary 
function and preventing pulmonary exacerbations5-6.   
 
1.3.1.2. Maintaining Nutrition 
 
Eighty-five percent of CF patients are pancreatic insufficient at birth and many follow the 
same path during their lifetime.  Bicarbonate secretion was also impaired in CF resulting in 
hostile conditions in the digestive tract.  The formation of enteric coated microspheres which 
resisted the effects of gastric acid in the 1980s was a development in the treatment of 
pancreatic insufficiency5.  Fat malabsorption resulted in the deficiency of fat-soluble 
vitamins; A, D, E and K.  Thus in 1989 the introduction of vitamin supplements was 
recommended25.  The inefficient circulation of bile and increased calorific demands due to 
chronic lung disease resulted in the necessity of nutritional supplementation27. 
 
1.3.1.3. Antibiotic Relief 
 
Since the introduction of antibiotics in 1944 aggressive, careful antibiotic treatment became 
gold standard in the prevention and treatment of lung disease28.  The development of oral 
antibiotics further radicalised treatment, though severe exacerbations were still treated 
intravenously.  The role of routine long term use of antibiotics to prevent of lessen 
pulmonary exacerbations is still under debate29. 
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1.3.1.4. Suppression of Inflammation 
 
Following the discovery of high levels of neutrophils and interleukin-8 in infants with CF 
compared to controls, the significance of suppression of inflammation was recognised and 
promoted6.  This was followed by the introduction of regular steroids.  However they were 
soon replaced by ibuprofen due to the resultant levels of side-effects.  Ibuprofen was later 
discouraged due to increased risk of gastrointestinal haemorrhage25.   
 
1.3.2. The Psychological Impact of Cystic Fibrosis  
 
By the late 20th century the significant role of the psychologist in the management of CF was 
recognised, particularly in paediatrics30.  The impact of CF on the QOL of the child was 
described as a significant focus of treatment and management.  There was now a secure 
place for the psychologist in the Multidisciplinary Team (MDT)31.  The need to measure 
QOL using Patient Reported Outcome Measures (PtROM) was recognised as a necessity 
encouraging research in this field32.  This progression has continued with an aim to improve 
the overall QOL of the child, the caregiver and the family33.
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2.1. Epidemiology of Cystic Fibrosis 
 
CF is the most prevalent, autosomal recessively inherited, life shortening disorder in the 
Caucasian populations with the highest incidence in Ireland34.  There are over an estimated 
10 million carriers of the gene worldwide and figures in 2004 showed that 50 000 people had 
been diagnosed with CF35.  There are over 7000 people diagnosed with CF in the UK and on 
average 1 in 2500 live births are affected22.   
CF was previously known as a short, painful disease of the young.  In 1938 the median 
survival age was less than 2 years6 36.  By 1989 the median survival age had risen to 26.5 
years and the current prognosis for infants born in the 21st century is over 30 years (Figure 2) 
22 37. 
 
 
Figure 2.1: The changing median survival age since cystic fibrosis was first accurately 
described6. 
 
 
The prevalence of CF is increasing in all populations.  Accordingly, the number of CF 
centres and research interests are increasing too.  Following recent medical advances it is 
estimated that the number of adults with CF is comparable to the number of children with 
CF38.  Elborn et al published up to date survival and population estimates in 1991 when 27% 
of patients in England and Wales were over the age of 1639-40.  They correctly predicted that 
as medical advances came into practice this figure would increase.  In 2003 Blau et al found 
that 30% of patients were above the age of 18 years and this proportion rose to 35% in 2005 
(Table 1) 6 36.  
 
 
 
This text box is where the unabridged thesis included the following third party 
copyrighted material: 
Median survival age for patients with CF at various times since the first description 
of CF. 
 
Davis PB. Cystic Fibrosis Since 1938.  
Am. J. Respir. Crit. Care Med. 2006;173(5):475-82. 
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Table 1: Mid-2003 cystic fibrosis population by age and sex 
The size of the 0 – 9 years age group were estimated from population births and survival data.  The 
size of the age groups of ≥ 10 years was based on data held by the UK Cystic Fibrosis Society38. 
 
 
2.2. The Aetiology of Cystic Fibrosis 
 
The CF gene codes for a cAMP-regulated chlorine channel, CFTR.  CFTR is a protein 
regulating transport of electrolytes across epithelial cell membranes41.  Since the gene was 
isolated, over 1600 mutations have been described22.  Mutations cause a dysfunction in the 
CFTR gene42.  The most prevalent mutation is seen at codon 508; the deletion of 
phenylalanine (phe508del) also referred to as Δ508.  This mutation accounts for over 70% of 
the CF chromosomes carried in the UK42.    
 
CF is a multisystem disease extending into adulthood affecting the respiratory, digestive, 
liver, pancreas and reproductive systems.  Most manifestations are attributed to the 
mutations in the CFTR gene however some symptoms remain elusive. The release of thick, 
viscous secretions affects the lungs, pancreatic ducts, intestines, biliary tree and vas deferens.  
The consequences include; irreversible lung pathology, bronchiectasis, chronic sinusitis, 
nasal polyposis, pancreatic insufficiency, intestinal obstruction, biliary cirrhosis and 
Congenital Bilateral Absence of the Vas Deferens (CBVAD) causing male subfertility41.   
 
The spectrum of disease caused by the different mutations is wide.  Respiratory, pancreatic 
and digestive functions all vary in severity with mutations carried (Table 2).    Some 
functions remain normal.  The mildest form of CF is found in males with no clinical CF yet 
CBAVD.  Heterozygote carriers of CF are at an increased risk of pancreatitis, sinusitis and 
 
This text box is where the unabridged thesis included the following third party 
copyrighted material: 
Mid-2003 cystic fibrosis population by age and sex 
 
Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival  
in the UK: 1947-2003. Eur Respir J 2007;29(3):522-6. 
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Allergic Bronchopulomonary Aspergillosis (ABPA)41.  Environment and therapeutic 
interventions can have an equal weight on disease outcome as genetic predisposition.  
Examples of environmental factors include exposure to tobacco smoke, poor socioeconomic 
status and lack of healthcare facilities25 43.   
 
 
Table 2: Classes of CFTR mutations adapted from Peebles et al25. 
 
 
2.3. Diagnosing and Screening Cystic Fibrosis 
 
Early diagnosis and treatment are essential in CF.  Aims of treatment are to prevent and 
reduce irreversible damage and prolong a good quality of life.  Screening identifies most of 
the cases of CF however false negatives are apparent and cases may go undiagnosed.  Due to 
variations in genotype and phenotype these patients may present with different 
manifestations to other specialities27.   
 
2.3.1 Indications 
 
All newborn babies in the UK are screened for CF at birth.  Those missed on screening are 
identified following presentation.  Symptoms found at presentation include5 25 27; 
1. Respiratory symptoms 
a. Chronic or recurrent cough 
b. Difficult asthma (20%) 
Class Effect on CFTR 
Type of 
Mutation 
CF Patients 
(Europe- %) 
Potential 
Therapy 
I 
Defective synthesis of 
message causing absence of 
CFTR 
Premature stop codon  
- either nonsense of 
frame shift (i.e. 
W1282X or G542X) 
7 Aminoglycasides Gene transfer 
II 
Abnormal CFTR produced 
which fails to leave 
endoplasmic reticulum 
Amino acid deletion 
or missense (i.e. 
ΔF508) 
85 Butyrates Gene transfer 
III 
Abnormal CFTR causing 
disruption of activation and 
regulation at cell membrane 
Missense mutation 
(i.e. G551D) <3 
Genistein 
Gene transfer 
IV Abnormal CFTR, reducing chloride conductance 
Missense mutation 
(i.e. R117H or R347P) <3 
Milrinone 
Gene transfer 
V 
Reduced or absent synthesis 
of CFTR due to decreased 
splicing of normal CFTR 
Missense mutation or 
splice site mutation 
(i.e. A445E or 5T) 
<3 Gene transfer 
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c. Purulent sputum 
d. Chest infection 
e. Nasal polyps 
f. Chronic sinusitis 
g. Pneumonia 
h. Unexplained haemoptysis 
2. Gastrointestinal symptoms 
a. Meconium ileus, meconium plug syndrome or echogenic bowel 
b. Prolonged neonatal jaundice, neonatal hepatitis syndrome 
c. Offensive diarrhoea and/or steatorrhoea (including Toddler’s diarrhoea) 
d. Failure to thrive 
e. Rectal prolapse 
f. Atypical gastro-oesophageal reflux 
g. Biliary cirrhosis, portal hypertension 
h. Hypoproteinaemia 
i. Anaemia 
j. Oedema 
3. Other symptoms 
a. Bulging fontanelle and facial palsy (vitamin A deficiency) 
b. Salty tasting sweat 
c. Heat exhaustion 
d. Rapid and prolonged skin wrinkling 
e. Short stature 
f. Delayed puberty 
g. Clubbing 
h. Appendicitis 
i. Pseudo-Bartter’s Syndrome 
j. Male infertility (CBAVD) 
k. International Normalising Ratio (INR) prolongation and abnormal bleeding 
caused by vitamin K deficiency  
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Table 3: Presenting features in unscreened Cystic Fibrosis25. 
 
 
2.3.2. Criteria 
 
CF is diagnosed following the presence of; 
1. Typical features as outlined above 
and 
2. Positive screening and/or a positive sweat test 
and/or 
3. The identification of 2 gene mutations 
Whilst recognising typical CF the criteria also identifies patients with symptoms suggestive 
of CF who don’t fit the criteria but still require treatment41. 
 
2.3.3 Newborn Screening - Immune Reactive Trypsin 
 
In 1979, a radioimmunoassay for IRT was developed27.  It allowed analysis of dried blood 
spots.  This method was employed in 2001 when the Department of Health recommended the 
introduction of Newborn Screening (NBS) for CF.  NBS tests for IRT levels in blood taken 
from newborn babies as part of the Guthrie Test27.  NBS came into practice in England in 
200644.  It reduces early hospitalisation and parental stress45.  Early accurate diagnosis 
through NBS also encourages a good relationship with the CF team24 46. 
 
In the first few weeks of life newborn babies with CF produce up to 5 times greater 
Presenting feature Percentage 
Gastrointestinal 30 
Respiratory 25 
Gastrointestinal and respiratory 15 
Meconium ileus 15 
Family history 10 
Other 5 
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concentrations of IRT than the normal population   Over the next few months this 
discrepancy is corrected.  Unfortunately, NBS yields a significant number of false positives 
as there is a similar rise in the level of IRT in the first week of life in the normal population  
 
2.3.4 Sweat Testing 
 
In the normal population, all sweat electrolytes are raised in the first 48 hours of life.  This 
level falls over the next 7 days.  In CF, sodium and chloride levels remain high14.  The level 
of chloride is proportionally greater than the level of sodium and 98% of patients have a 
significantly higher level of chloride.  Sweat testing assesses the level of chloride 
specifically47.  The process used is pilocarpine iontophoresis.  Currently, two methods are 
employed; the Gibson and Cooke method and the Wescor Macroduct system48. 
 
 
Table 4: Levels of Sweat Chloride and Diagnosis25. 
 
 
Sweat testing is unpopular in young children as obtaining the required amount of sweat can 
be difficult.  Preterm babies may not sweat for a few weeks and young children produce 
lower quantities of sweat48.  
 
2.3.5 Genotyping 
 
Genotyping is gold standard for diagnosis.  Once Deoxyribonucleic Acid (DNA) is obtained 
from mouthwash samples, buccal scrapes or white blood cells27 samples are tested for the 
most common CFTR mutations.  The identification of 2 CFTR mutations supports a 
diagnosis of CF.  If only 1 CFTR mutation is detected despite high suspicions rarer 
mutations are tested for23.  Due to the large and varied number of mutations, genotyping can 
lack sensitivity and may need repeating for rarer mutations.  Genotyping is carried out in 
patients who have been diagnosed through other methods, for confirmation.  It also provides 
Level of Chloride Detected Diagnosis 
< 40 mmol/L Normal 
40  - 60 mmol/L Borderline  
> 60 mmol/L Cystic Fibrosis 
> 150 mmol/L Error 
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further information regarding their phenotype41.  It is common practice to check the genotype 
of all siblings following the positive diagnosis of a child49. 
2.3.6. Nasal Potential Difference 
 
Due to the electrolyte imbalances described above, patients with CF have a greater negative 
NPD.  NPD across the respiratory epithelium is measured by inserting probes in both nasal 
cavities following the instillation of ionic solutions.  Whilst the test is specific it requires 
expertise and is only carried out in specialist centres.  It is also sensitive to slight changes 
caused by infections, surgery and allergic rhinitis, producing false positives41. 
 
2.3.7. Other Methods 
 
Other tests are available to confirm suspicions if routine tests are inconclusive.  These 
include; sinus radiographs, bronchoalveolar lavage, tests for exocrine pancreatic function, 
tests for malabsorption and semen analysis23 41.  These tests also help recognise CF related 
disease including CBAVD50. 
In 2000 the World Health Organisation (WHO) released a new classification recognising CF 
related disease25 45 51: 
1. Classic CF (pancreatic insufficient) 
2. Classic CF (pancreatic sufficient) 
3. Atypical CF 
4. CF (otherwise specified) 
5. CF (not otherwise specified) 
6. Isolated obstructive azoospermia (1 CFTR mutation) 
7. Chronic pancreatitis (1 CFTR mutation) 
8. Allergic bronchopulmonary aspergillosis(1 CFTR mutation) 
9. Disseminated bronchiectasis(1 CFTR mutation) 
10. Diffuse panbronchiolitis(1 CFTR mutation) 
11. Sclerosing cholangitis(1 CFTR mutation) 
12. Neonatal hypertrypsinogenemia 
 
2.4. The Clinical Manifestations of Cystic Fibrosis 
 
CF manifestations can be unique to individuals due to variations in phenotype.  Symptoms 
can vary significantly between individuals and treatments are tailored to their specific 
needs50.   
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2.4.1. The Respiratory System 
 
Lung disease is the main cause of morbidity and mortality52.  Ninety seven percent of CF 
patients die of respiratory causes.  Twenty percent of patients have coexistent asthma and 
atopy whilst a further 10% develop ABPA27 53. 
Symptoms include an increased frequency and severity of coughing, an increase or change in 
the colour of sputum, increased shortness of breath, poor exercise capacity, haemoptysis, 
anorexia and weight loss5.  These are detected clinically by a decrease in lung function, 
auscultation and changes on chest X-ray. 
Patients with CF encounter the same number of infections as the normal population but they 
are more likely to be symptomatic.  Bacterial infections are found in patients at an early age 
and aggressive antibiotic therapy is required36.  The lack of water in secretions and the 
viscosity of mucus in airways contribute to the risk of infection.  It is the repeated cycle of 
infections which leads to the colonization of organisms in the lungs.  This causes the clinical 
respiratory features of CF.  Staphylococcus aureus and Haemophillus influenza are isolated 
early.  Pseudomonas aeruginosa may be found at later stages in the disease27.  This is 
followed by a marked decrease in lung function.  Burkholderia cepacia, is a pan-antibiotic 
resistant strain of bacteria with the potential to cause rapid pulmonary decline and can lead to 
death54.  Repeated infection results in a persistent neutrophillic inflammatory response and 
an increased volume of secretions.  These eventually impact areas of the respiratory tract and 
destroy the walls25 55.  To avoid colonisation CF patients are regularly screened for 
respiratory infections.   
 
2.4.2. The Gastrointestinal System 
 
Maintaining a good nutritional status in patients is imperative to treatment.  Eighty five 
percent of CF patients are pancreatic insufficient.  And despite recent advances 
approximately 20% of children and 40% of adults are diagnosed with nutritional failure27.   
Thirty percent of patients not diagnosed at birth, present with gastrointestinal symptoms 
including meconium ileus or other forms of intestinal obstruction and recurrent rectal 
prolapse25 27 51.   
Symptoms commonly displayed are Gastroesphageal Reflux (GOR), abdominal pain, 
diarrhoea and constipation.  It is not uncommon for the symptoms to be a result of other 
treatments.  Poor adherence to medication must also be considered as a cause. 
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2.4.3. Diabetes Mellitus and Glucose Intolerance 
 
Prevalence of Diabetes Mellitus (DM) and endocrine pancreatic insufficiency increases 
above the age of twelve36.  Pancreatic fibrosis leads to further decrease in insulin producing 
beta cells.  A good history enquiring about symptoms of general malaise, polydipsia, 
polyuria and weight loss are necessary.  It is good practice to monitor blood glucose, glucose 
tolerance, urinanalysis and glycosylated haemoglobin annually.   
 
2.4.4. Liver disease 
 
Liver disease naturally develops in the first 2-10 years in 18-37% of patients.  Five percent 
of these go on to develop cirrhosis and portal hypertension, a further 2.5% develop variceal 
bleeding and 2-3% require liver transplantation25 27.  
 
The abnormal CFTR is located on apical membranes of epithelial cells lining intrahepatic 
ducts leads to bile duct obstruction and destruction causing focal biliary cirrhosis.  CF can 
also cause, fatty infiltration leading to secondary hepatomegaly, gallstones, liver cirrhosis, 
portal hypertension causing chronic liver disease56.  Patients present with acute variceal 
haemorrhage, haematemesis, aspiration and respiratory deterioration5. 
 
2.5. Treating and Managing Cystic Fibrosis 
 
Management of CF requires prompt MDT communication and involvement.  The CF team 
consists of consultants, nurses, dieticians, physiotherapists, pharmacists, psychologists and 
most importantly the caregivers and family of the patient57.   
 
2.5.1. The Respiratory System 
 
Respiratory failure due to lung damage is the main cause of premature death in CF6.  
Respiratory treatment aims to prevent long term irreversible lung damage.  This requires 
careful prevention, early detection and eradication of organisms to delay chronic 
colonisation. It involves thorough, regular surveillance including, detailed histories, 
monitoring lung function including Forced Expiratory Volume in 1 minute (FEV1) and 
Forced Vital Capacity (FVC), regular sputum culturing and taking chest X-rays.  Symptoms 
are reviewed at 2 – 3 month intervals 
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Four areas of management include efficient airway clearance, administration of antibiotics, 
maintaining a good nutritional status and physical fitness.  This involves careful delivery of 
antibiotics, anti-inflammatories, mucolytics and physiotherapy25 58. 
Whilst Staphylococcus aureus and Haemophillus influenza are the main source of primary 
infection, 80% of adults with CF are chronic carriers of Pseudomonas aeruginosa27.  
Pathogen specific antibiotics are administered both orally and intravenously for a period of 
10 to 14 days.                                                                                                                                                                                                                     
Treatment includes respiratory physiotherapy, inhaled nebulisers and steroids and oral and 
intravenous antibiotics. The progressive nature of CF results in the need for continual 
invasive treatment.  This can impact negatively on the patient, their family and their 
caregiver’s lives57.   
 
2.5.1.1. Physiotherapy 
 
Patients are referred to the physiotherapy team at diagnosis for information regarding 
physiotherapy regimes and support.  The physiotherapist is an important member of the CF 
team and must be included in the treatment of any inpatient. 
 
Physiotherapy aids airway clearance, promotes exercise and maintains mobility and posture.  
Airway clearance reduces airway obstruction, improving ventilation and delaying disease 
progression.  Exercise improves cardiovascular and respiratory fitness and strength, whilst 
ultimately improving lung function.  Whilst stretching and strengthening exercises maintain 
and restore good posture25 59. 
Patients are reviewed at 2 – 3 month periods.  This includes an assessment of their disease 
status, sputum collection, a review of airway clearing techniques, advice on general fitness 
and mobility and posture.  All patients are seen annually as part of the annual assessment.  
This includes a complete demonstration of airway clearing techniques, exercise tolerance 
tests and inhaler and nebuliser technique review60. 
 
2.5.1.2. Lung transplantation 
 
Lung transplantation offers a new lease of life for those with lung failure.  The first lung 
transplantation on record was performed in 1983.  At present more than 200 people received 
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new lungs each year.  The current survival rate is 80% at one year, 64% at three years and 
less than 50% by year 425 27. 
2.5.2. The Gastrointestinal System  
 
The concept of prevention, detection, slowing progression and preventing complications also 
apply in the treatment and management of gastrointestinal manifestations.  Regular 
surveillance includes monitoring height and weight, abdominal examination for 
organomegaly, abdominal ultrasound scans, liver function tests and monitoring faecal 
elastase levels46.  
Maintaining nutrition is vital.  CF patients require up to 150% of the normal calorie intake 
due to increased respiratory efforts61.  This is achieved through an increased intake of high 
calorific foods where possible and supplemented with calorie powders and glucose drinks 
where required.  Due to fat malabsorption and maldigestion the fat soluble vitamins A, D, E 
and K are supplemented alongside minerals and sodium.  Irregular bowel habits are managed 
through correcting dehydration, using oral lactulose, gastrograffin, laxatives and Pancreatic 
Enzyme Replacement Therapy (PERT).  Symptoms of GOR are managed with antacids, and 
Proton Pump Inhibitors (PPI), prokinetcics and changing bowel habits25.  Where 
conventional nutritional encouragement fails it may be necessary to introduce overnight 
feeding in the form of enteral nutrition; nasogastric or gastrostomy.  This is usually 
introduced during pubertal years to maximise growth potential52.   
 
2.5.3. Diabetes Mellitus and Glucose Intolerance  
 
Twelve percent of patients over the age of 13 have Type I DM and the prevalence increases 
with age at a rate of 5% per year25.  Patients are encouraged not to conform to the normally 
recommended diabetic diet due to the increase calorific requirement though a reduction in 
sugar intake is advised.  CF related DM responds well to insulin27 62.   
 
2.5.4. Liver Disease 
 
Symptoms of liver disease are initially relieved by ursodeoxycholic acid.  Hepatic steatosis 
and gallstones occur in 15% of patients and are treated with surgery.  Liver transplantation 
provides permanent relief25 56. 
 
2.5.5. Complications 
 
Complications of CF include nasal polyps, sinusitis, anosmia, musculoskeletal problems 
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which eventually affects 14% of patients, delayed puberty, subfertility problems and 
difficulties during surgical, anaesthesia and analgesia5 52. 
2.6. Organisation of Cystic Fibrosis Care 
 
Most patients are managed at local specialist centres.  Patients may be seen annually at major 
specialist centres which have a dedicated team, training and research specific to the 
management of CF.  National resource centres specialise further and carry out 
transplantations.  All patients are ideally seen every 2 months for routine investigations and 
prescription changes.  Regular prescriptions may be repeated by general practitioners. 
 
2.6.1. Shared Care of Cystic Fibrosis 
 
Shared care brings together information about patients at a local and national level in order 
to alleviate travel and expense burden on the patient’s family.  Whilst patient care is based at 
one centre referrals may occur to other specialist centres.  Joint clinics allow specialist staff 
from larger centres to attend peripheral clinics at a regular basis.  Despite joint clinics 
patients should still be seen at specialist centres regularly. 
 
2.6.2. The Annual Assessment Process 
 
Annual assessments take place once a year and provide significant information relating to the 
treatment and management of the patient.  They include height and weight measurements, 
full blood counts, liver function tests, urea and electrolytes, glucose tolerance tests in 
patients over the age of twelve, abdominal ultrasound, posterior-anterior chest X-ray, 
audiology tests, lung function tests, exercise tolerance testing, review of airway clearance 
techniques, review of inhaler and nebuliser techniques, physiotherapist assessment and 
assessment of nutritional status by a dietician.  The assessment can last up to 4 hours and 
usually takes place at a national resource centre or major specialist centre.  Much of this time 
is spent in waiting areas and the experience can be tedious and unwelcome by the child and 
the caregiver.   
 
Feedback of the results occurs at the next outpatient appointment which is followed by a 
detailed letter outlining the results, any discussion that took place at the appointment and any 
change in treatment.  Results and changes are compared to the outcome of the previous 
year’s annual assessment. Any change in treatment is discussed at the MDT meeting. 
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The literature search was conducted on OvidSP using the Ovid MEDLINE(R) (1948-2009) 
database.  An advanced search was conducted to locate articles with the key words, “Cystic 
fibrosis,” and “Quality of life,” in their titles and abstracts.  The Boolean operators, ‘AND,’ 
OR,’ and ‘NOT’ were used to ensure the inclusion and exclusion criterion was fulfilled.  The 
inclusion criteria ensured that all studies; 1) discussed the topic of QOL in CF paediatric 
patients, 2) were on humans, 3) were available in English.  Within this selection a sub 
category of articles which included the terms, “Questionnaire,” OR, “Outcome measure,” 
OR, “Patient reported,” OR, “Parent reported” was also included.  A number of keywords 
were, ‘exploded,’ to allow for the international variation of terms used.  
 
The information extracted from this section of the literature search was used to both signify 
the effect of CF on the QOL of the caregiver and to evaluate the need for a robust and 
accurate method of measuring QOL in patients and caregivers.  The latter part of the 
literature review focussed on the properties of a good PROM and was used to inform the 
methodology of this study.  The results of fifteen primary studies were mapped to compare 
outcome.  Five studies were further appraised to assess the methods employed and the 
properties of the questionnaires developed or adapted.  Studies were selected from the search 
results in accordance to the validity of the methods employed and the choice of the outcome 
measure.  The pre-existence of a number of tools available to measure QOL in children with 
chronic disease and CF specifically was noted.  The lack of such tools applicable to their 
caregivers was apparent.  Specifically, a gap in studies looking at QOL in caregivers was 
identified. 
 
The second half of this chapter focuses on the concept of SE, its role in caregivers of 
children with CF and the possible benefits of equating SE and mapping change in relation to 
disease management.  SE is not a novel concept.  But research relating SE to the role of 
caregivers is relatively recent.  Research concentrating on caregivers of children with chronic 
disease is further finite.  There is no current literature connecting SE in caregivers to the 
management of CF in children.   
 
This literature search was less succinct due to the lack of specific literature available.  The 
Ovid MEDLINE(R) (1948-2010) database was used to find articles containing the term, 
“Self efficacy,” in the title.  The research was further refined by combining the search with 
the term, “caregiver” in the article body.  To allow for international variance of terms the 
MeSH heading, “Caregiver” was exploded to include a further 14 terms.  Articles were then 
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further subdivided to those including the term, “chronic disease” and “paediatric.”  Articles 
located at each stage of this particular search thread were saved.  The inclusion criteria 
included 1) the language English and 2) human subjects. 
 
‘Full texts’ for all articles were located using Ovid MEDLINE(R) (1948-2010) and the 
University of Liverpool Electronic-Journal Database and transferred to Endnote.  To assess 
for congruence identical searches were conducted on Scopus and ScienceDirect.  All articles 
were further reviewed, analysed and critically appraised with regards to the validity of their 
results.  The critical appraisal tool used is an adapted format of a tool proposed by Guyatt et 
al63.  This tool offers a simple yet robust method of analysis of studies whilst allowing easy 
comparison between methodology and conclusion. 
 
As stated there is no current published data available assessing the role of SE in caregivers of 
children with CF and mapping the changes against disease management.  Whilst the use of 
PROM has been exhausted in previous years their impact on caregivers and their ability to 
influence SE has not been studied to date.  The literature review verified this hypothesised 
gap in recent studies.  
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Life 
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3.1. Defining Quality of Life 
 
Caring for a child with CF can be expensive, exhaustive and requires a great deal of time and 
patience.  Involvement of the MDT is imperative to this care.   
Pain and discomfort are side effects of the disease and its treatment; headaches, chest pain, 
abdominal pain, back pain, limb pain, arthritis and neuropathic pain are all examples of types 
of pain that may be encountered. It is reasonable to assume that CF dramatically disturbs the 
QOL of the patient, the caregiver and the family unit including siblings. 
Life expectancy of patients with CF is increasing as a result of recent medical advances.  
Measuring the impact of the chronic illness on patients is considered important64.  Over 3 
decades ago the WHO published a definition for health, 
“a state of complete physical and social well being, not just the absence of disease65.” 
Subsequently, time and resources have since been allocated to improve QOL in patients and 
over the past 2 decades numerous tools have been proposed to measure QOL. 
Paediatric medicine aims to improve the patient’s, their caregiver’s and the family unit’s 
global QOL where possible alongside stopping or slowing down disease progression.  The 
disease and its treatment prevent the child from carrying out many Activities of Daily Living 
(ADL).  Measuring QOL is a method of subjectively evaluating the impact of chronic 
disease on a patient’s ADL and global well being.  QOL is, “a dynamic psychological 
construct, which describes the subjective health perceptions of the patients independently of 
objective health parameters,”66.  It fluctuates over time and disease progression amongst 
other factors. 
 
3.2. Measuring Health Related Quality of Life using Patient Reported Outcome 
Measures 
 
Over the past 25 years Patient Reported Outcomes (PtRO) have become increasingly 
important and greatly influence the treatment received.  Considerable work has been carried 
out to develop tools to equate and evaluate PtRO.  A (Patient Reported Outcome Measure) 
PtROM is, 
 
“a measure of a patient’s health status, elicited directly from the patient, that assesses how 
the patient feels or functions with respect to his or her health condition67.” 
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Outcome measures range from items rating a single symptom to a multisystem analyses 
looking into the global Health Related Quality of Life (HRQOL) of the patient. HRQOL 
measurements in CF allow the inclusion of a patient’s perspective. 
HRQOL is a multidimensional construct.  It includes the domains of physical functioning, 
social functioning and emotional and psychological functioning.  They give an overall 
picture of the disease state incorporating otherwise untested for states.  This includes anxiety 
and depression68.  At present, there are 3 types of PtROM commonly used to measure 
HRQOL69. 
 
3.2.1. The Utility Model 
 
The utility model considers the economic decision theory, assessing the impact of disease 
and comparing the costs and value of available treatments.  The Quality of Well-Being 
(QWB) scale is an example of this model65.  The outcome is a single value between 0 and 1 
which represent overall health status.  It allows cost-utility analyses to be performed and 
plays a major role in clinical trials70-71.  Utility models lack sensitivity and aren’t suitable for 
use in paediatrics. 
 
3.2.2. The Health Profiles Model 
 
This represents a general health model of which the Child Health Questionnaire (CHQ) is an 
example.  It offers reliable measurement in a wide range of disease states and has the 
advantage of ease.  But it is non-specific and lacks sensitivity.  Even with approved 
reliability and validity it has limited use to patients with CF. 
 
3.2.3. The Disease Specific Model 
 
Proceeding the discovery of the CF gene, the National Institute of Health Research stated the 
need for a disease specific measure of HRQOL for patients with CF69.  The resultant model 
would look specifically at the domains which affect CF patients and calculate their QOL 
accordingly.  The Cystic Fibrosis Questionnaire (CFQ) is an example of this model. 
From diagnosis, depending on disease stage and rate of progression, patients with CF are 
subject to numerous, invasive investigations and interventions72.  Studies show that this 
fluctuating disease state and treatment has a direct causal influence on HRQOL 54 73.  QOL 
correlates positively with lung function and improves significantly post lung 
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transplantation66.  There is a need to monitor HRQOL when assessing the physical health of 
any child with CF 54 74. 
 
3.3. Review of Commonly used Patient Reported Outcome Measures 
  
Fifteen studies were reviewed and a further five articles critically appraised to assess 
commonly used PtROM. 
Measures reviewed included; the utility measure QWB scale, the generic measures; CHQ, 
Short Form-36 (SF-36) and the QOL scale and the disease-specific measures, CFQ, Cystic 
Fibrosis Questionnaire-Revised (CFQ-R) (for all age groups and parents), Cystic Fibrosis 
Quality of Life (CFQOL), Questions of Life Satisfaction-Cystic Fibrosis (FLMZ-CF) and 
Caregiver Quality of Life Cystic Fibrosis (CQOLCF) Scale used for assessing caregivers.  
The Beck Youth Inventories (BYI) and Hospital Anxiety and Depression Scale (HADS) 
measures looking at psychosocial aspects of living with CF were also included. 
Three disease-specific models were studied in further detail; CFQ-R, CFQOL and the 
FLZM-CF.  The CFQ-R was most user friendly and had both a child and parent version.  
Work has been done to develop a pictorial version.  The latter two have been used on both 
adults and adolescents however not on children67. 
Both the methods employed in these studies and their findings are relevant to this research.   
3.3.1. Summary of Studies  
 
Table 5; Summary of 15 studies into the Use of Patient Reported Outcome Measures in 
Clinical Practice 
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Linguistic validation of cystic 
fibrosis questionnaires75 –Rozov 
et al 
To validate the Portuguese translations of 4 CF QOL 
questionnaires (CFQ); CFQ 6-11 years, CFQ 12-13 years, 
CFQ >14years and CFQ parents of children aged 6-13 years, 
respectively. 
Multicentre sample from 
3 CF centres with sample 
size estimation from past 
experience 
Cross sectional 
study - 
comparative 
aspect checked for 
reproducibility 
2 
sessions 
over 15 
days 
150 4 
The translation and cultural adaptation for Brazil resulted 
in 4 CFQ versions that are easy to understand and offer 
good reproducibility. 
Differences between adolescents’ 
and parents’ reports of health-
related quality of life in cystic 
fibrosis76 –Britto et al 
To determine the magnitude and direction of differences 
between adolescents with CF and their parents’ reports of 
the adolescents’ HRQOL as measured by the adolescent and 
parent versions of the Child Health Questionnaire (CHQ) 
Formal invitation prior 
to routine clinic visit at a 
CF centre 
Comparative 
study – formed 
part of an 
extended cohort 
study. 
1 session 
over 1 
visit 
124 2 
Adolescents tended to rate their HRQOL better than their 
parents.  They also rated themselves less susceptible to 
illness and worried less about their health. Optimal 
measurement of adolescent HRQOL will require 
determining both parent and adolescent perceptions of 
HRQOL. 
Validation of a disease-specific 
measure of health-related quality 
of life for children with cystic  
fibrosis74 – Modi et al 
To evaluate the psychometric properties of the CFQ -Child. 
Recruited from 22 
centres across the United 
States during routine 
clinic visits whilst 
waiting for consult 
Cross sectional 
study with multi-
trait analyses 
1 session 164 1 Results demonstrated that the CFQ – Child is a reliable and valid measure of HRQOL for children with CF. 
Associations between clinical 
variables and quality of life in 
adults with cystic fibrosis54 – 
Gee et al 
To explore associations between clinical variables and 
HRQOL using the Cystic Fibrosis Quality of Life 
questionnaire (CFQOL) 
All patients from 2 
regional CF centres 
considered eligible 
Cross sectional 
study – multiple 
regression 
analysis 
6 months 
223 
adult
s 
1 
Whilst important associations were identified, much of 
the variance remains unexplained and merit further 
investigation.  A longitudinal study is required to 
investigate further effects on QOL 
Effect of disease-related pain on 
the health of children and 
adolescents with cystic fibrosis73 
– Palermo et al 
To describe the effect of recurrent pain symptoms on the 
HRQOL of children and adolescents with CF using the 
CFQ-Revised (CFQ-R) 
Recruited on basis of 
availability from 3 
university/community 
based paediatric CF 
outpatient clinics  
Cross sectional 
study – with 
multivariate 
analysis of 
variance 
3 months 46 2 
Children with frequent CF-related pain experience broad 
decrements in HRQOL.  Future research requires 
evaluation of the treatments used to reduce symptoms and 
improve QOL. 
Can health-related quality of life 
predict survival in adults with 
cystic fibrosis?77 – Abbott et al 
To evaluate whether patient-reported HRQOL could predict 
survival in CF using the CFQOL and SF-36. 
Approached consecutive 
patients from 2 adult CF 
clinics 
Observational 
cohort study of – 
with death used as 
an endpoint 
10 years 223 1 
Aspects of patient reported QOL serve as prognostic 
measures of survival beyond a number of previously 
known factors in CF.  This needs to be investigated 
further in a larger longitudinal study. 
Health-related quality of life in 
adults with cystic fibrosis: the 
role of coping78– Abbott et al 
To examine the role of coping in explaining HRQOL in CF 
using CFQOL. 
125 consecutive patients 
attending a Regional 
Adult CF Unit.  
Cross sectional 
questionnaire 
design 
2 
sessions 125 1 
Coping is an important factor in explaining some QOL 
domains but not others.  This has important implications 
especially when employing HRQOL as an outcome 
measure in clinical trials. 
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Psychological and family 
functioning and quality of life in 
adolescents with cystic fibrosis79 
– Szyndler et al 
This study examined the interrelationships between QOL, 
family functioning, individual psychopathology and 
optimism of adolescents with CF using CFQ and the 
Family Environment Scale.  
All inpatient and 
outpatient adolescents 
approached over 8 
months 
Cross sectional 
multiple 
questionnaire 
study 
1 session 
(time 
varied) 
52 1 
Adolescents with CF appear to be a psychologically well 
functioning and well-adjusted group.  A more 
sophisticated model of well-being for adolescents with 
CF, which explores their views on  QOL is required in a 
follow up study. 
Living with cystic fibrosis; 
impact on global quality of life80 
– Wahl et al 
To examine the impact of living with CF from a global 
quality of life perspective using Norwegian version of the 
QOL Scale. 
Control group drawn 
randomly; intervention 
group based on CF status 
Cross sectional 
comparative 
design 
16 
months 1107 2 
Results suggest the existence of a type of response shift 
in the CF group through changes in life standards and 
goals.   
Development and validation of 
the cystic fibrosis questionnaire 
in the United States81 – 
Quittner et al 
This study evaluated the psychometric properties of the 
CFQ in a national study. 
Recruited from 18 CF 
centres across the United 
States pending consent 
Cross sectional 
comparative study 
–  
multi-trait 
analysis 
10-14 
days 212 2 
Results demonstrate that the CFQ-teen/adult is a reliable 
and valid measure of HRQOL for individuals with CF.  It 
may be utilised in clinical trials to assess the effects of 
new therapies and to document the progression of 
disease. 
Quality of life in patients with 
cystic fibrosis: association with 
anxiety and depression68 – 
Havermans et al 
To investigate whether CF patients with symptoms of 
anxiety or depression reported lower HRQOL scores using 
the Hospital Anxiety and Depression Scale (HADS) and the 
CFQ. 
 Recruited consecutively 
from an adult CF centre 
outpatient clinic 
Cross sectional 
study – analyses 
of variance 
1 session 57 1 
Preliminary evidence was found on the role of anxiety 
and depression in different areas of QOL in CF, which 
may help in the development of appropriate medical and 
psychosocial treatment programs. 
Quality of life of children with 
cystic fibrosis69 – 
Koscik et al 
To review HRQOL and associated issues and to describe a 
study investigating CHQ scores in relationship to Newborn 
Screening (NBS) for CF and markers of disease severity. 
Patients previously 
enrolled on a randomised 
prospective study 
Cross sectional  
comparative study 1 session 36 2 
Results did not demonstrate a benefit of CF NBS on 
QOL.  This may be due to the lack of sensitivity of the 
CHQ in comparison to the disease specific CFQ, for 
example. 
Psychosocial problems in 
children with cystic fibrosis82 – 
Bregnballe et al 
To compare the well being of children (7-14 years) with CF 
with the well being of healthy controls using the self-report 
questionnaire Beck Youth Inventories (BYI). 
Invited for recruitment 
from a children’s CF 
centre 
Comparative 
study 8 months 1164 2 
Children with CF did not differ from the norm when 
concerning depression, disruptive behaviour and self-
concept.  However there were significant differences in 
anxiety and levels of anger. 
The caregiver QOL CF 
(CQOLCF) scale: modification 
and validation of an instrument 
to measure quality of life cystic 
fibrosis family caregivers83 – 
Boling et al 
To modify the caregiver quality of life index – cancer scale 
as the CQOLCF scale, validate it with CF family caregivers 
and assess caregiver QOL with patient disease severity. 
Recruited on the basis of 
CF family caregiver 
status from unknown 
location 
Descriptive 
observational 
study 
Time 
scale not 
detailed 
100 1 
The CQOLCF appears to be valid, reliable and internally 
consistent disease-specific scale with family caregivers.  
Future research recommendations include administering 
the CQOLCF to an increased study sample to explore 
item factor analysis. 
Cross cultural differences in 
heath related quality of life in 
adolescents with cystic fibrosis84 
– Abbott et al 
This study compared QOL between English and German 
adolescents with CF and their healthy peers using the SF-36. 
Consecutive outpatients 
attending 3 CF clinics in 
3 locations were invited 
to join 
Comparative cross 
sectional study 
Time 
scale not 
detailed 
208 4 
Differences in quality of life between English and 
German adolescents with CF appear to be either 
culturally determined or due to idiosyncrasies in the 
translations of the SF-36, rather than a consequence of 
their disease or its management. 
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3.3.2. Critical Appraisal  
Table 6; Study 1 –Validation of a disease-specific measure of health-related quality of 
life for children with cystic fibrosis74 (Modi et al) 
Criteria Success in addressing the criteria 
Screening questions 
Did the trial address a 
clearly focussed research 
question? 
An objective was clearly outlined and followed throughout.  A sound 
conclusion answering the initial research question was reached as a result 
of the study. 
Did the authors use the 
right type of study? 
An appropriate method was employed to analyse the results of the study.  
The CFQ was administered to the participants and a multi-trait analysis 
was applied to the results. 
Detailed questions 
Was the assignment of 
patients randomised? 
Patients were recruited from 22 specialist centres according to the inclusion 
criteria which included a strict outpatient status.  There were no major 
modifiable discrepancies between participants although social statuses 
were diverse.  Randomisation was not employed. 
Were all the participants 
who entered the trial 
properly accounted for at 
its conclusion? 
Eighty four child participants were accounted for throughout the study 
including the method, results and conclusion.  The parent group had  eighty 
participants. 
Were participants, health 
workers, and study 
personnel ‘blind’ to 
treatment? 
Research coordinators completed specialised training to standardise study 
protocol between sites during recruitment and screening.  There was no 
mention regarding the input of these coordinators in neither assisting 
participants complete the CFQ nor the setting where they were completed.  
Blinding did not take place. 
Were the groups similar 
at the start of the study? 
There were two groups of participants, child patients with CF and their 
parents.  There was no need for matching and adjustments. 
Aside from the 
intervention were the 
groups treated equally? 
There is little mentioned regarding the actual method employed in 
addressing participants.  
Outcome 
Are the results of the 
study judging by the 
method employed valid? 
Patients were not uniquely selected for this study.  Only 168 patients were 
used.  This being a relatively small sample results in a lower power and 
consequently less convergence of the results.  Precaution was taken 
regarding the validity of the results.  Research coordinators completed 
specialised training in order to standardise the study protocol across sites 
and the patients were matched for confounding factors.  Gender and age 
differences were checked for. 
Are the results of the 
study consistent and 
reliable? 
Previous literature concords with the results of the study.  Effort was made 
to ensure that participants with results from the extremities were checked 
on.  Multi-trait analysis was performed and paired correlation was 
calculated. 
Can the results be 
applied to the local 
population? 
The 84 participants and their parents were recruited from 22 centres across 
the United States and are a sound representation of the population.  Patients 
were approached during routine visits whilst waiting for appointments, 
which was a realistic approach.   
Were all clinically 
important outcomes 
considered? 
The majority of the data yielded positive results though not all and no 
associations were found between pulmonary function and CFQ scores.  
However, the extremely ill were not included in recruitment and this cohort 
is most at risk of poor HRQOL.  Young children also have difficulty 
expressing emotions to parents and on paper. 
Will the results help locally? 
Are the benefits worth 
the harms and costs? 
The purpose of this study was to recognise the reliability and validity of the 
CFQ-Child to aid health professionals treat their patients.  This was done 
accurately and the model proposed no physical harm to patients in the 
general population.  There was concern however, over the psychological 
impact of the questionnaire.  
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Table 7; Study 2 - Effect of disease-related pain on the health-related quality of life of 
children and adolescents with cystic fibrosis73 (Palermo et al) 
Criteria Success in addressing the criteria 
Screening questions 
Did the trial address a 
clearly focussed research 
question? 
The objective was clearly outlined and justified with reference to the 
literature.  The research question was answered adequately. 
Did the authors use the 
right type of study? 
46 children were subjects of a retrospective pain interview following the 
successful completion of the CFQ-R.   
Detailed questions 
Was the assignment of 
patients randomised? 
Participants were invited to participate via letters from 3 different 
paediatric outpatient CF clinics.  All patients listed were invited.  Letters 
were followed up at 2 and 4 weeks with phone calls.  36.8% of those could 
not be contacted again.  Some chose not to participate, others couldn’t 
schedule the time.  46 patients participated.  Selection was opportunistic 
not randomised. 
Were all the participants 
who entered the trial 
properly accounted for at 
its conclusion? 
All participants who consented to participate in the trial were accounted 
for.  However, 8 participants had been excluded from the start due to 
missing date in their files. 
Were participants, health 
workers, and study 
personnel ‘blind’ to 
treatment? 
There was no requirement for blinding in this study.  All participants were 
given the same information.  Questionnaires were not anonymous.  
Were the groups similar 
at the start of the study? 
The two groups were determined by age and had no influence on the 
results as this was not a group comparative study.  Matching did not take 
place  
Aside from the 
intervention were the 
groups treated equally? 
There is no mention of how the groups were treated.  The investigations 
were carried out on all patients and all participants were given a $10 video 
rental gift. 
Outcome 
Are the results of the 
study judging by the 
method employed valid? 
The sample size was very small, predominantly Caucasian and drawn from 
only one centre; hence the results had a limited diversity and low power.  
Most patients experienced mild disease.  patients with extreme symptoms 
were excluded.   
FEV1% measurement took place up to 2 months after the questionnaire 
was completed; this may have skewed results.  Patients were asked to 
recall any pain experienced 4 weeks prior of the date of the study, this may 
have been difficult particularly for children and introduced recall bias.  The 
pain scale was an 8-point scale.  Again these may have been difficult for 
the children to complete. 
Are the results of the 
study consistent and 
reliable? 
Previous literature results are consistent with these results. 
Can the results be 
applied to the local 
population? 
Pain is an important factor of CF and is an issue with most CF patients.  
This study showed that pain reduces HRQOL of patients.  This is an 
important factor to consider when monitoring patients. 
Were all clinically 
important outcomes 
considered? 
This study used a single HRQOL measure; pain and this reduced the 
efficacy of the results substantially. 
Will the results help locally? 
Are the benefits worth 
the harms and costs? 
This study reports no harm and the benefits are substantial in the 
monitoring and treatment of patients. 
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Table 8; Study 3 – Quality of life in patients with cystic fibrosis: association with 
anxiety and depression68 (Havermans et al) 
 
 
Criteria Success in addressing the criteria 
Screening questions 
Did the trial address a 
clearly focussed research 
question? 
This study had a succinct aim to address, one that has yet to be covered by 
previous literature covering HRQOL in CF patients. 
Did the authors use the 
right type of study? 
A cross-sectional study design was applied to compare participants’ 
HRQOL scores related to their Hospital Anxiety and Depression Scale 
(HADS) scores, which assessed the level of anxiety and depressive 
symptoms experienced. 
Detailed questions 
Was the assignment of 
patients randomised? 
Patient selection was not randomised.  Consecutive patients attending a CF 
clinics were invited to participate in the study. 
Were all the participants 
who entered the trial 
properly accounted for at 
its conclusion? 
All participants were accounted for at the start and end of the study.  No 
participant left the study prematurely. 
Were participants, health 
workers, and study 
personnel ‘blind’ to 
treatment? 
This study did not require blinding to take place.  The timing and order of 
the different measurements including lung function is not mentioned, 
however. 
Were the groups similar 
at the start of the study? 
There was only one principal group in this study.  Only post-results were 
group devised. 
Aside from the 
intervention were the 
groups treated equally? 
It is not possible to deduce which way the results flowed; it is equally 
possible that the lower HRQOL came after the anxiety and depression.  It 
is also equally possible that these results are also apparent in the non-CF 
population.  HADS is not a diagnostic tool, it is commonly used for 
screening and the results must be followed up accordingly. 
Outcome 
Are the results of the 
study judging by the 
method employed valid? 
This study showed that the prevalence of anxiety and depression is no 
different in the CF population than the normal population.  However, the 
sample size in this particular study was relatively small and patients at the 
far end of the disease scale were not included in the study. 
Are the results of the 
study consistent and 
reliable? 
Previous literature has shown that both anxiety and depression are more 
common in the chronically ill population and due to the limitations of this 
study these results may not be reliable. 
Can the results be 
applied to the local 
population? 
Poor pulmonary function may be associated with increased levels of 
anxiety and depression in patients with CF.  These results may help 
identify these patients in clinical practice. 
Were all clinically 
important outcomes 
considered? 
This study focussed primarily on the prevalence of anxiety and depression 
in patients suffering with CF,  
Will the results help locally? 
Are the benefits worth 
the harms and costs? HADS is simple to use and takes little time to complete.  It is viable and reliable as a screening tool.  This study provides good preliminary evidence 
regarding the correlation between anxiety and depression and HRQOL in 
patients with CF, showing that screening is important in this group. 
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Table 9; Study 4 – Quality of life of children with cystic fibrosis69 (Koscik et al) 
 
Criteria Success in addressing the criteria 
Screening questions 
Did the trial address a 
clearly focussed research 
question? 
This study aimed to answer a specific question.  CHQ scores were 
compared in patients who entered the NBS programme for CF to a control 
group who did not. 
Did the authors use the 
right type of study? 
Patients involved in a previous Randomised Controlled Trial (RCT) 
involving screening in new born babies were enrolled on this randomised 
prospective study according to the diagnosis of CF.  All patients were then 
treated equally. 
Detailed questions 
Was the assignment of 
patients randomised? 
Patients were borrowed from a previous randomised prospective study 
which was still in place.  Only 2 CF centres were used.  This limited 
variability and representation of the true population.  
Were all the participants 
who entered the trial 
properly accounted for at 
its conclusion? 
Only 36 of the 89 original patients enrolled in this study and all were 
accounted for throughout.  The others were excluded due to age 
specifications.   
Were participants, health 
workers, and study 
personnel ‘blind’ to 
treatment? 
There was a control group but no blinding was in place.  The control group 
was that of a previous study.  For the purpose of this study all patients were 
treated equally. 
Were the groups similar 
at the start of the study? 
The independent variable was the study group which compared the results 
between the initial control and screened group from the previous trial.  
There were also 6 more people in the control group than in the normal 
group.   
Aside from the 
intervention were the 
groups treated equally? 
The groups had been treated differently in the previous study.  One group 
was screened for CF at birth the other was not. 
Outcome 
Are the results of the 
study judging by the 
method employed valid? 
Although an interviewer recorded all results reducing recording error, 
patients were asked to recall information from the past 4 weeks leaving 
room for recall bias.  All but 1 of the patients were of white origin.  Due to 
sample size this study had low power.  The results of the study were 
negative showing that NBS has little effect or no effect on HRQOL in later 
life.  The validity of the results is questionable and it would be advisable 
for this study to be repeated. 
Are the results of the 
study consistent and 
reliable? 
No other studies of this nature are present in previous literature. 
Can the results be 
applied to the local 
population? 
NBS for CF is already in place in England.  However, the importance of 
measuring HRQOL is outlined in the study. 
Were all clinically 
important outcomes 
considered? 
All clinically important outcomes were considered. 
Will the results help locally? 
Are the benefits worth 
the harms and costs? 
The study reports no harm to the patients who were not screened for CF 
and furthermore shows that their HRQOL remains unaffected.  The 
questionnaire used is reported to take only 20 minutes to complete which 
will be of use in clinical practice. 
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Table 10; Study 5 – Psychosocial problems in children with cystic fibrosis82 (Bregnballe 
et al) 
 
Criteria Success in addressing the criteria 
Screening questions 
Did the trial address a 
clearly focussed research 
question? 
This trial addresses a clearly focussed research question looking in detail at 
the subject of psychosocial problems faced or experienced by patients with 
CF. 
Did the authors use the 
right type of study? 
A controlled cohort study compared results from a control group which 
were recycled from an earlier study to the results from a group of 
participants who had CF. 
Detailed questions 
Was the assignment of 
patients randomised? 
Over a period of 8 months all patients who met the inclusion criteria were 
invited to participate in this study.  Socioeconomic status was accounted 
for. 
Were all the participants 
who entered the trial 
properly accounted for at 
its conclusion? 
1 patient declined to participate in the study.  All other patients were 
accounted for throughout the study. 
Were participants, health 
workers, and study 
personnel ‘blind’ to 
treatment? 
There was no need for blinding in this study.  All patients were treated the 
same.  The same person instructed all participants on how to fill in the 
questionnaire.   
Were the groups similar 
at the start of the study? 
There were two groups in this study.  A control group consisting of the 
population who did not have CF.  This was of a good sample size; 1121.  
The intervention group consisted of only 43 participants.   
Aside from the 
intervention were the 
groups treated equally? 
Both groups were asked to fill in the Beck Youth Inventories (BYI).  There 
is no mention of where and how the questionnaires were completed or over 
what time span. 
Outcome 
Are the results of the 
study judging by the 
method employed valid? 
Study sample size was small compared to the control sample.  
Consequently, the power was small.  The age range used was 7-14 years of 
age.   Children are not always well informed about their disease and they 
may have been too young to understand what was asked in the 
questionnaire. 
Are the results of the 
study consistent and 
reliable? 
The study showed psychosocially children with CF performed no 
differently in the BYI compared with the normal population, though some 
areas such as anxiety and anger differed.  However, due to the differences 
in sample size this is not a reliable result. 
Can the results be 
applied to the local 
population? 
Both anxiety and depression are prevalent in the normal population and in 
the CF population.  Previous studies have shown that both these states can 
affect behaviour and disease state in patients with CF.  It may be important 
to use a screening tool such as the BYI in clinical practice. 
Were all clinically 
important outcomes 
considered? 
HRQOL was not taken into consideration in this study.  This is an 
important concept which may have helped illustrate any existing 
correlation. 
Will the results help locally? 
Are the benefits worth 
the harms and costs? 
Although the study group did no differ from the norm it is still a valid 
acceptable test and important to perform in clinical practice.  The authors 
did not comment on harms. Those patients who were screened positively 
benefitted. 
37 
 
Table 11 – Disease-specific patient reported outcome measures for health related 
quality of life in children with Cystic Fibrosis67 85-86 
M
easure 
D
om
ains 
Target Population 
Tim
e 
O
rder  
O
f 
 R
eliability 
V
alidity Internal 
C
onsistency 
Test-R
etest 
CFQOL 
- 9 domains 
- 52 items 
Physical / Social 
Treatment Issues 
Chest Symptoms 
Emotional Responses 
Concerns for Future 
Interpersonal 
Relationships 
Body Image 
Career 
14 years 
+ Unknown 2 2 
• Discriminates between 
disease severity 
• Sensitive to changes FEV1 
and BMI (IV antibiotics) 
• Correlates with SF-36 
scores 
CFQ-R 
Child 
- 8 domains 
- 35 items 
Physical 
Emotional State 
Social 
Body Image 
Eating 
Treatment Burden 
Respiratory 
Digestion 
6 years + 15 minutes 
5 
1 
• Discriminates between 
children with CF and 
healthy children 
• Discriminates between 
disease severity  
• Sensitive to changes FEV1 
and BMI (IV antibiotics) 
• Correlates with PedQL 
CFQ-R 
Adolescent 
- 12 domains 
- 50 items 
Physical / Social 
Emotional State 
Body Image 
Eating 
Treatment Burden 
Respiratory 
Digestion 
Role 
Vitality 
Health Perceptions 
Weight 
1 
• Discriminates between 
disease severity 
• Sensitive to changes FEV1 
and BMI (IV antibiotics) 
• Correlated with FEV1 and 
BMI 
• Correlates with SF-36 
CFQ-R 
Parent 
- 11 domains 
- 44 items 
Physical 
Emotional State 
Body Image 
Eating  
Treatment Burden 
Respiratory  
Digestion 
Vitality  
School 
Weight 
3 
• Discriminates between 
disease severity 
• Sensitive to changes FEV1 
and BMI (IV antibiotics) 
• Correlates with SF-36 
FLZM-CF 
- 9 domains 
9 items 
Breathing Difficulties 
Coughing  
Abdominal Pain 
Digestive Trouble 
Eating 
Sleep 
Routine Therapy 
Adherence to Daily 
Therapy 
Significance for 
Others 
Understanding  
Free from 
Disadvantage 
16 years 
+ 
5 
minute 4 3 
• Discriminates between 
disease severity 
• Correlates with FEV1 and 
time spent on treatment 
• Responsive to change after 
impatient rehabilitation 
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The table illustrates how all 3 measures are valid.  On average the CFQ-R and CFQOL Scale are most 
reliable and comprehensive however only the CFQ-R has been validated for use with children.  The 
FLZM-CF is brief and only worthy as a screening tool67 78. 
 
 
 
3.3.3. Analysis of Methods Employed to Measure Quality of Life 
 
All of the studies analysed were descriptive in nature and most were cross-sectional.  Cross-
sectional studies are inexpensive and simple.  They enable the study of many conditions at 
once and can be used to measure the needs of patients.  This type of study is ethically safe 
hence ideal in paediatric patients with CF.  They involve four simple procedures; 
observation, measurements, questioning and studying records.  Studies explored a link 
between the variables of QOL and the change in disease progression.  Unfortunately, this 
type of study is subject to recall bias and must have a high response rate or sample size to 
maintain power.  It can be subject to bias and skewed outcomes.  Causality is not assessed.  
This makes it difficult to show association.  Cross-sectional studies show prevalence not 
incidence by collecting data from a snap shot in time.  This is ideal as the results may help 
shape future management.  Unfortunately, optimal, reliable results are formed when the 
samples are large and random.  In most of the studies this was not the case.  This could be 
due to a diagnosis of CF being a requirement68-69 75 79.   
Patients were outpatients in most studies hence the patients suffering from severe symptoms 
were not included.  This is the group whose QOL is most affected66.  Patients who opted not 
to take part may have done so due to the severity of their disease73 87-88.  It was found that 
patients with greater insight into the disease lived a cautious lifestyle, sometimes in isolation 
in a bid to prevent infections and complications.  Their expectations may have been lower 
hence subsequent QOL was subjectively higher77. 
Many factors correlate with changing QOL in patients with CF; disease state, hospital 
admissions, treatment, concurrent and past medical history, socio-demographic factors, 
gender, culture, Body Mass Index (BMI), schooling environment, family dynamics and 
psychopathology43 65-66 68 80 84 89.  No single study at all aspects. 
The methodology of most studies consisted of assessing PtROM however little weight was 
put on where and when measures were taken.  In some studies the study participation was 
pre-planned whilst others were approached in the waiting room prior to their appointment.  
Some participants may have prepared for the study73-74.  The study setting was also subject to 
change.  Some studies took up to 20 minutes to complete the PtROM other studies gave 
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participants a pack of questionnaires to take away.  The order of questioning also varied.  
Where some patients were given lung function results others weren’t73.  Such discrepancies 
may have skewed results dramatically and may have introduced substantial recall bias both 
between and within studies54 66 76.  Patients may have also withheld information due to 
embarrassment79.  HRQOL measuring tools are highly subjective and can be sensitive to 
small changes.  Results can be unreliable depending on personal judgement and coping 
ability66.   
Where parents were included in studies it was found that they tended to rate QOL up to12 
points lower on average than their children76 90.  This may reflect on their personal QOL and 
the Burden of Care (BOC) they experience90.  As a primary caregiver the parent’s QOL 
impacts on the management of the child’s disease at home.  There is a need for the 
assessment of primary caregivers together with the assessment of family functioning as a 
whole. 
 
3.3.4. Analysis of commonly used Patient Reported Outcome Measures 
 
CF is a complex and difficult to treat paediatric condition and an important health issue.  The 
multisystem nature of CF requires regular MDT involvement, routine appointments and 
hospital admissions89.  Patients’ perceptions of health are skewed compared to the normal 
population.  This is referred to as a response shift.  This results in an altered threshold for 
changes in HRQOL80.  It would explain how all studies involving parents deduced that the 
patients rated their QOL higher than their parents did76.  Individual coping mechanisms 
differ considerably between patients and caregivers and this is reflected in the PtROM 
results68 78.  Gee et al and Quittner et al showed that gender and cultural differences also 
exist with regards to coping and the subjective interpretation of the illness and its global 
effects65 84 87 91.  Females experience lower levels of anger than males and higher levels of 
anxiety.  Male subfertility in adulthood worries many male patients too70 75.  Another 
example is the lower BMI which is often seen in patients; where females are happier with 
being lean the males interpret the symptom as embarrassing and take measures to avoid 
public display54 81.  Although emphasis must be put on educating patients66 factors such as 
the expected shortened life span, male infertility and reduced QOL may cause undue stress80. 
Certain risk factors; low birth-weight, poor pulmonary function, airway pathogens, anxiety 
and depression put patients at greater risk of a poor QOL72 77 86.  Measuring HRQOL in these 
patients may not be as valuable as their baseline HRQOL may be considerably lower73 78.   
Presently, the CFQ-R is the most widely used HRQOL measure in CF72.  Recognised 
internationally and translated into 25 languages it has drastically changed CF care and 
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research92.  Both the CFQ-Child and CFQ-Parent should be regularly incorporated into the 
annual assessment to maintain benefits72.  It has a potential to increase responsiveness70 75 
and could be computerised and used to formulate patient profiles92.  These could be 
monitored closely by both the family and the MDT.  With the addition of screening devices 
such as HADS and BYI a global image of HRQOL can be attained. Both the American 
Thoracic Society and European Respiratory Society have recommended that screening be in 
place and treatment given86.   
Screening tools are inexpensive and simple to administer.  It is beneficial to incorporate 
screening into the annual assessment to check for easily missed disorders.  It is acceptable 
that due to naïve reading levels and understanding and poor recall and attention in children 
such measures are difficult.  Some of the symptoms of anxiety and depression like fatigue 
are commonly seen in CF and care must be taken to distinguish these.  BYI enquires about 
sensitive issues such as suicide.  It is however difficult to comprehend and is not ideal in 
children.  As with all screening measures the subsequent outcome both positive and negative 
can have affects on all parties involved.  A true positive result, whilst alerting the CF team, 
could also lead to further medicalisation of their life; a change that may not be welcomed by 
the individual.  A false positive would lead to further unnecessary screening and possibly 
treatment.  It could also disturb the relationship between the patient, the caregiver and the CF 
team. 
It may be argued that the HADS and BYI measures are not significant as they do not 
measure QOL directly.  The psychosocial aspects taken into consideration have been shown 
to have adverse effects on compliance, treatment and mood62 84.  Patients in this group tend 
to engage in smoking and drinking and consequently have a greater number of hospital 
admissions86.  Anxiety and depression reduce emotional arousal and can also lead to eating 
disturbances and low self esteem68 86.  Larger studies have shown that depression rates are as 
high as 50% in medical populations compared to 17.2% in the healthy population86.  It is 
widely accepted that anxiety and depression are also more prevalent in patients with chronic 
disease.  Professional input from a psychologist or psychiatrist is vital in the screening of 
such disorders as compliance may diminish resulting in a reduced QOL68,86 93.   
The Hunter Opinions and Personal Expectations Scale (HOPES) showed that the majority of 
patients were hopeful with regards to their management of CF and their future79.  CF patients 
are psychologically well adjusted and live normal, happy successful lives.  It is not the fatal 
childhood disease that it used to be.  The main aim now is to monitor and optimise QOL. 
An important issue raised is that of whom HRQOL measures should be aimed towards.  
Ultimately the QOL of the patient is empirical to the management however in the case of 
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paediatric CF where disease management is heavily weighted on the caregiver it may be of 
benefit to involve them too.  The use of HRQOL measures on parents and caregivers is vital 
as they usually share the burden and are at times more anxious than the children due to their 
higher level of understanding76 90.  Bregnballe et al showed that parents worried about BMI 
more than children as children lacked understanding and in the case of adolescent female a 
lower BMI was often preferred82.   
CF is a condition which affects the family as a whole influencing family dynamics and 
reshaping important decisions.  CF influences the home environment and general mood.  The 
state of the disease influences compliance with daily, complex, time consuming treatment93.  
It is noted that there is a substantial maternal demand sometimes interpreted as burden by the 
family and caregiver.  This can cause negative feelings and anger from all parties concerned.  
Increasing support is being offered to caregivers as the role can result in a lack of rest and 
sleep, fatigue, health problems, anxiety, fear, depression and financial difficulties83.  Recent 
studies have shown that depression is common in parents and caregivers, particularly 
following diagnosis86.  Boling et al found that the CQOLCF is a valid and reliable measure 
taking all aspects of the caregiver’s well-being into account83. 
The generation of a flawless PtROM with the ability to take into consideration and be 
sensitive to every aspect of CF is a sophisticated science and will take time to be perfected.  
Measurement of HRQOL in CF has a lot to offer in future advances both to research and 
care71. 
 
3.4. The Challenges of Living with Cystic Fibrosis Questionnaire – A Parent Reported 
Outcome Measure 
 
The CLCF-Q is a 10 part, 62 item PROM measuring the burden of care on a 
parent/caregiver.  It relies entirely on Parent Reported Outcomes (PRO) to equate the burden 
of living with the everyday challenges faced by the caregiver of a child with CF. 
The development of the CLCF-Q began in 2005.  It stemmed from the gap in literature 
identified by the Mental Health Unit and the Institute of Child Health at Alder Hey 
Children’s NHS Foundation Trust; a need for a research tool focussing on the caregiver94.  
Glasscoe et al aimed to, 
“Capture the experience of bringing up a child with cystic fibrosis3.” 
Much time, attention and revenue is focussed on measuring the QOL of the child and its 
changes in relation to health; HRQOL.  Little attention has been given to the focal entity; the 
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caregiver of the child in question.  In most areas of medicine and in particular paediatrics, 
the caregiver plays an essential role in the disease outcome having determined the treatment 
and management received by the child at home.  Thus it is imperative that their health is also 
considered.  The burden of caring for a child with a chronic disease and overcoming the 
challenges of living with CF can have detrimental effects on the caregiver64.  The QOL of 
the caregiver and the effect of the BOC on their QOL should be considered.  No measure of 
caregiver challenge currently exists. 
Using the avenues of selective consultation through in depth cognitive interviews, focus 
groups and active research involving parents and caregivers (n = 10) and the CF MDT the 
basic operative themes were constructed; demographic characteristics, family context, 
child’s character, CF history, challenge to family life, CF routines, local medical service and 
supplies, hospital based care and pharmacy with careful consideration of time and effort 
exercised94. 
The present study forms part of a collection of studies looking into the development and 
validity of the CLCF-Q.  The CLCF-Q was devised to take between 15 – 30 minutes to 
complete requiring minimal effort and employing the use of Likert scales.  Pilot data (n = 39) 
supported face validity, acceptability and reliability establishing the CLCF-Q as a useful tool 
to employ94.   
The CLCF-Q aims to explore the themes of time and complexity of tasks and challenges 
estimating the demand on caregivers.  It can be used to explore the effects of BOC on 
adherence and compliance.  Most importantly it can help correlate changes in the BOC and 
consequently, QOL.  Both the mental and physical health of the caregiver must be 
considered.  Stress, depression and anxiety are all physiological states strongly associated 
with the BOC.  
The CLCF-Q was recently used in the Home Intravenous Antibiotic Therapy (HIVAT) study 
as an outcome measure in a study estimating risk95.  Dyer et al also showed that the CLCF-Q 
was sensitive to changes in disease.  Pulmonary exacerbations resulted in increased time 
demands and resultant BOC96.  This supported the face validity of the CLCF-Q in measuring 
BOC.  Both studies examined the change in score of the CLCF-Q over two time point’s 
relative to disease state.   
The CLCF-Q is a multidimensional tool suitable as a research outcome in clinical trials, as a 
clinical tool in practice and perhaps most importantly as an indirect psychological 
intervention for caregivers by aiding feedback97-98.  In a previous study caregivers expressed 
the value of the CLCF-Q as an essential piece in the annual assessment process94.  They 
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recognised its potential to detect changes in their child’s condition and equate their coping 
by privileging their personal views.  It helped to reflect on their experiences and recorded 
their coping abilities of complex challenges.  The recollection also helped identify areas of 
concern.  Diverting the focus from the child’s HRQOL to the caregiver’s challenges. In 
theory, allowing us a deeper understanding of caregiver challenge.   
“It offers a framework for caregivers to raise any difficulties and has potential as a clinical 
tool at annual review as well as a research tool in clinical trials.3” 
It has a strong potential to reveal where challenges lie allowing the identification  of 
negatively impacting factors99.   
An issue arising from previous studies is the need for meanings to be associated with 
interventions.  The basis of this present study were built on the concept of using the CLCF-Q 
to identify otherwise unrecognised issues encountered by caregivers when facing challenges.  
Through the process of careful feedback following the completion of the CLCF-Q a deeper 
understanding of the challenge would be gained by both parties.   
44 
 
 
__________________________________________________________________________ 
 
Self Efficacy 
 
_______________________________________________________________________ 
45 
 
 
4.1. The Concept of Self Efficacy  
 
It is human nature to strive for control in any situation.  Through control we are able to 
guarantee the desirable goals in life and avoid disappointments.  It is reasonable to assume 
that our belief in our ability to attain an achievement determines our choice of activities and 
our general demeanour towards the situation.  This includes effort expended, our 
sustainability, our resilience, our perseverance and essentially the level of anxiety 
experienced.   
In 1977 Albert Bandura published his works on, ‘Self Efficacy,’ coining the phrase and 
paving the way for a new field of interest100-101.  
“Perceived self efficacy refers to people’s belief in their capabilities to organise and execute 
the courses of action required to deal with prospective situations102.” 
- Bandura, 1977 
Human behaviour develops through careful modelling techniques101 103.  Initially one may 
observe and follow others or instructions given by others.  Later one will learn from others or 
one’s own mistakes allowing for self corrective adjustments until the technique is refined to 
a suitable standard.  One’s Perceived Self Efficacy (PSE) dictates ones will to face 
challenges.  This is due to the dependence on coping beliefs104-105.  Without PSE or with a 
low PSE the task is seen as too great a challenge and may be avoided completely or 
performed with no intent to succeed; hence poorly106.   
PSE is a standalone concept and must not be confused with the other ideologies of global 
self esteem, locus of control and self confidence107-108.  Expectations of personal SE 
ultimately determine whether or not an action is initiated109.  It holds significant promise and 
may help to explain the variability in a person’s ability to cope with the demands and 
challenges which arise from caring for a chronically ill patient.   
Expectation is devised from two angles; efficacy expectation and outcome expectation.  
Whilst efficacy expectation refers to personal SE and belief in one’s ability to complete a 
task, outcome expectation refers is, “A person’s estimate that a given behaviour will lead to a 
certain outcome101.”  The difference between efficacy expectation and outcome expectation 
is that the subject may believe in the outcome but they may doubt their personal ability.  
Expectations affect both initiation and persistence of coping behaviour and in order to 
maintain efficacy they must succeed, performing well consistently.   
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Psychological techniques can help create and strengthen SE.  It is hypothesised that those 
who persistently face challenging situations will eventually overcome their inhibitions 
through corrective experience; learning from their mistakes100.  Thus overcoming barriers 
and facing challenging situations must be encouraged in order to promote coping 
behaviour110-111.  Unfortunately, it is also possible to adapt a defensive behavioural pattern 
which can be debilitating112.  
To date the SE model has been used in many areas of treatment and research.  The initial 
focus of SE research was on phobias, chronic stress and coping.  In health, it has now moved 
on to experiences of family caregivers of dementia patients and more recently chronically ill 
paediatric patients113-115.  Whilst research has considered SE studies with CF patients the 
concept of measuring and influencing SE in caregivers of children with CF has not been 
looked into116. 
 
4.2. Influencing Self Efficacy 
 
‘An odd aspect of the perceptual control theory is the claim that, “People act to control the 
perceptions, and not actions104 117.”’ 
- Vancouver et al 
PSE is shaped through four main routes; performance accomplishments, physiological states, 
vicarious experience and verbal persuasion101-102 104.  
 
4.2.1. Performance Accomplishments 
 
When a task is performed successfully the resulting sense of accomplishment and personal 
mastery increases the individual’s SE.  The methods employed to confront the challenge are 
retained as information.  This learned behaviour enables the individual to repeat the task with 
ease.  Having completed the task previously the task faced no longer seems a challenge101 104.  
Through this repetitive notion a greater number of challenges are faced successfully 
lessoning the perception of burden. 
 
4.2.2. Vicarious Experience 
 
Vicarious experience refers to an individual modelling the actions of another on their own103.  
Seeing another overcome a similar task successfully reinforces one’s belief in their personal 
ability to face that challenge.  Furthermore when facing the task they mirror the actions 
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witnessed.  Unfortunately, previous studies have shown that vicarious experience alone is 
not effective in noticeably improving SE100 107. 
 
4.2.3. Verbal Persuasion 
 
The ease of use and ready availability of ideal situations promotes the use of verbal 
persuasion as an ideal source of information.  Using appraisals and feedback individuals may 
be persuaded and encouraged to face overwhelming situations98. Studies have shown that 
social persuasion in the appropriate environment and corrective performance are more likely 
to work than performance alone100 107.    
 
4.2.4. Physiological States 
 
We rely heavily on emotional arousal when determining the appropriate reaction to a 
situation118.  Situations causing a heightened sense of emotional arousal are deemed stressful 
and result in anxiety119.  Individuals often surrender as a result of the associated anxiety114.  
As previously described for performance accomplishments this sensation is reinforced 
further when the task and associated anxiety are faced again100 107.   
 
4.3. Influencing Self Efficacy – In Practice 
 
In order to ensure the maximal increase in SE all four sources of impact should be utilised, 
but this isn’t always possible.  The optimum method for maximising SE in any given 
situation would be to eliminate all sense of anxiety completely100 104 107 120.  But this isn’t 
usually possible either. 
SE regulates human behaviour via motivational, cognitive, affective and decisional 
processes109 121.  It can be used to influence actions both positively and negatively.  Evidence 
from meta analyses have consistently illustrated that SE contributes significantly to 
motivation and performance104 109.  There is also evidence showing that negative persuasion 
manifests stronger than positive persuasion hence more effort is required to positively 
influence a situation than negatively104.  It is important to consider how each performance is 
unique and independent and whilst simultaneous situations may affect each other no 
situation can be imitated wholly.  Furthermore the more difficult a challenge the greater the 
number of positive persuasions required to enforce positive SE and the greater the influences 
are taken into consideration; both positively and negatively107. 
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Stimuli do not change in condition and cannot be influenced in any way.  It is one’s 
knowledge of the situation and the perceived environment of the challenge that can be 
influenced.  Our reaction to the stimulus dictates this100-101 104. 
This study couples the concepts of performance accomplishments with verbal persuasion by 
exploring the use of a PROM in a clinical setting; namely the CF annual assessment.  It 
studies the use of the tool the CLCF-Q to increase how able the primary caregiver feels in 
managing the everyday challenges they face as a consequence of caring for a child with CF.  
Unlike previous research in similar areas, this work does not aim to eradicate defensive 
behaviour.  Instead it focuses on corrective behaviour and empowerment. 
 
4.4. Assessing Self Efficacy 
 
Assessing SE can be as complicated as influencing SE.  The German version of the General 
Self Efficacy-Scale (GSE-S) was developed in 1979 by Matthias Jerusalem and Professor 
Ralf Schwarzer122.  They discussed how PSE reflected on optimistic self belief and was 
required to facilitate goal setting and persistence in everyday activities123.  The scale was 
originally developed to help equate general PSE and allowed the assessor to predict the 
individual’s ability to cope with daily challenges and recover following stressful life 
experiences123.  It has been translated in 26 languages and the measure has been used 
successfully for 3 decades.  Originally designed for children and adults over the age of 12 it 
consists of 10 items graded on a 4-point Likert scale and yields a score between 10 and 40.  
The recommended completion time is up to 4 minutes.  The GSE-S has previously been 
tested for reliability with Cronbach’s alpha values of 0.75 – 0.91 (median = 0.80)122 124. 
The GSE-S can be amended to include disease specific items.  This study assesses the SE of 
caregivers in the field of CF.  Four additional non-validated items specific to caring for a 
child with CF will be added to the GSE-S to cater for this. 
 
4.5. The Role of Self Efficacy in Stressful Situations 
 
When asked about the role of the caregiver the word most often used to describe their 
situation is, ‘stressful.’  But it is not the situation itself that causes discomfort, it is the 
concept of losing control of the situation104 107 125.  Correlation exists between low SE and 
increased anxiety.  This poor belief in your ability to succeed in the situation is the main 
stressor.  Stressful situations elicit emotional arousal debilitating performance further120 126.   
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Experiments have shown that levels of stress are lowest when faced with an equally 
challenging situation to one which has been completed before in comparison to unfamiliar 
situations101.  This is directly related to the higher level of SE maintained as a result of 
having completed the task before; previously described as performance accomplishment.  
When exposed to unfamiliar challenging situations which are perceived as difficult to tackle 
the resultant PSE is low.  PSE mediates anxious behaviour.  Improving an individual’s PSE 
reduces the level of stress they experience104. 
Ideally, focussing on reducing emotional arousal and anxiety would allow caregivers to 
manage their physiological arousal and take control of situations but this is not possible 
within the constraints of outpatient hospital care125. 
There are two prominent theories which consider the concept of SE as pivotal in human 
response to stressors.  The social learning theory recently referred to as the social cognitive 
theory, considers anxiety and defence mechanisms as coexistent factors which aren’t 
causally linked.  It takes the relationship between physiological arousal and performance as 
being inversely proportional.  SE is seen as the focus with an increased SE being the cause of 
lower physiological arousal. The dual process theory states that eliminating anxiety will by 
definition eradicate defensive behaviour as they are directly linked126-127.    
Early research into SE centred largely on reducing the affect of and eliminating phobias.  
The role of systemic desensitisation was explored and yielded promising results112.  To 
eliminate defensive behaviour we must ultimately reduce or eliminate anxiety126.  Systemic 
desensitisation to common stressors would be ideal but due to the constraints of the 
outpatient clinic this is not possible.   
The social cognitive theory defines human self development as a product of constant 
adaptation to change101.  Using this theory the possibility of influencing and improving an 
individual’s reaction to a challenge is feasible.   
Two main principles construct human behaviour; cognitive processes and performance-based 
procedures.  Through modelling, we observe others, succeeding in our efforts and 
consequently forming new behaviour patterns.  This is termed observational learning and 
leads to learning appropriate behaviour patterns through personal experience103 118.  
Consequences of actions, inform performers which behaviours are appropriate and which 
aren’t; which behaviours yield positive results and which lead to disappointment.  This 
reasoned information is processed serving as an experience of mastery.  Experiences of 
mastery improved PSE towards a specific challenge whilst also improving global SE105 120. 
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This study looks at the possibility of assessing and influencing SE.  The aim is to empower 
the caregiver and reduce the amount of stress experienced.  The ideal result would improve 
the overall QOL of the caregiver and the family unit. 
We aim to incorporate a recently developed and validated burden of care measure called the 
CLCF-Q into the annual assessment process.  It details items concerning the caregiver’s role 
which aren’t regularly visited during clinic appointments.  Issues will be identified from the 
CLCF-Q and simple feedback offered at a later appointment.  Allocated time with specific 
members of the CF care team, to discuss any previously unidentified issues will follow.  The 
identification and solution of challenges or problems using the theories of performance 
accomplishment and verbal persuasion may increase SE whilst decreasing anxiety and 
reducing defensive behaviour126.   
Positive behavioural change is proportional to change in PSE127-128.  Behaviour is based on a 
background of thought and in order for SE to be affected subjects must recognise paired 
stimulation; cause and effect.  They must understand that the outcome was the direct result 
of the action129.   
Through careful specific feedback and verbal persuasion the meaning of challenges and 
situations can be revaluated significantly98 104.  It is worth noting that feedback information is 
synthesized and processed over relatively long periods of time so the effects are not normally 
expected to manifest instantly.  The likely change in SE is gradual.  This is similar to 
avoidance behaviour which persists for long periods after the situation and stressors have 
passed106.   
 
4.6. The Role of Self Efficacy in Promoting Quality of Life 
 
PSE facilitates goal-setting, effort investment, persistence, and recovery.  It is an operative 
construct relating to subsequent human behaviour and notably relevant to clinical practice107.  
Human behaviour has equitable control over QOL.  And SE dictates behaviour hence PSE 
has an indirect influence on QOL105.  To promote the QOL of the caregiver, SE must be 
monitored, reviewed, adjusted and maintained.   
Exploring the SE levels of caregivers of children with CF would detail the scope and 
differences in SE between different caregivers and family units.  It would allow the 
identification of cases with particularly poor levels of SE.  It can also be used as an indicator 
of QOL at any locus.  As a result it may be possible to influence and improve the SE of these 
caregivers.   
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Generally, positive habits and perseverance must be encouraged as accomplishments lead to 
satisfaction.  Through repeated success the individual gains a sense of control.  A global 
sense of personal control and mastery reduces depression and increases coping ability125 130. 
PSE also fosters the development of supportive relationships126 131.  It is this sense of a 
supportive environment which is imperative to a good QOL.  Incorporating an intervention 
into routine care which aims to identify areas which the individual recognises as a challenge 
and following this with careful constructive feedback and support, will allow the healthcare 
team to influence SE, perceived control and inevitably QOL.  Such an intervention would 
also improve perceptions of availability of social support120. 
 
4.7. The Role of Self Efficacy in Caregivers of Children with Cystic Fibrosis 
 
CF is a unique disease specific to each individual.  Similarly, the SE and coping ability of the 
caregiver are also unique to that individual111.  Different children with CF require differing 
levels of care depending on their disease state.  This has an impact on the burden of care and 
the QOL of the primary caregiver. 
The role of the caregiver is emotionally, mentally and physically challenging114.  Caregivers 
often express difficulties confronting and regulating their worries about the future.  Whilst 
the use of cognitive and behavioural therapy is usually aimed at reducing anxiety it may also 
be helpful in developing coping strategies126.  Coping efficacy reduces anxiety and 
depression130.  
Originally much of the research carried out on the concept of SE worked around the 
treatment of phobias.  Recently this has moved to the role of caregivers caring for children 
with chronic disease, mainly cancer131-136.  Whilst SE contributes significantly to coping and 
anxiety levels it must not be confused with the concept of developing coping strategies and 
reducing anxiety.  SE has a distinctive and significant role to play in health, particularly 
paediatric health.  The care of a paediatric patient has more dimensions than the care of an 
adult.  Caregivers of the paediatric patients play a pivotally influential role in the outcome of 
the disease.  In the chronic, intensely demanding disease CF caregivers are expected to 
tackle a wide range of treatments and make decisions on a day to day basis.  CF is now 
moving rapidly towards home based care.  This dramatic shift has vast implications on the 
role of the caregiver and the family unit.   
In the normal environment it is understandable that challenging situations are avoided106.  
However, as the primary caregiver of a chronically ill child difficult situations must be faced 
on a daily basis and cannot be avoided.  Persistently facing challenges reinforces a higher 
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level of SE107.  A greater level of PSE in any given situation is often associated with mastery 
and success101.  By positively influencing SE the aim is to empower caregivers; though 
caregivers must believe that the outcome of any given action will be equally positive each 
time.  Over time performance in similar situations is improved and a generalised increase in 
SE is noted.  Enhanced SE can become generalised over time improving reactions to all 
situations faced.  Contrarily, repeated failures within a short span of time and early on in the 
learning process result in dramatically lower general SE levels resulting in long lasting 
negative cognitions.   
This study uses a PROM and feedback as tools to improve the SE of an individual.  For this 
to be successful one must understand that feedback involves more than simply informing a 
patient of the findings.  It is more than informing them that a treatment will work and a 
certain situation can be overcome.  Carefully constructed and successful feedback is a two 
way process.  It involves simultaneous interaction between the practitioner and the caregiver.  
Any interventions and changes to management must be illustrated and the path must be 
explained.  The caregiver must believe that their views have shaped the discussion and are 
valued.  Feedback should not only inform the caregiver it must also involve them.  It is 
proposed that in the specific situation of caregivers of children with CF feedback must be 
followed by specifically allocated time with the healthcare team.  This is to allow any 
concerns to be addressed104 107.   
This study proposes that handing over a proportion of control to the caregiver will improve 
their SE125.  More importantly helping caregivers understand how their control is exercised 
and giving them a direct avenue through which to seek help would further alleviate stress 
and anxiety.  This avenue would be the inclusion of the CLCF-Q in the annual assessment 
process. 
Psychological changes can be achieved through many different methods and modes of 
treatment.  They all have the potential to alter SE100.  The impact of the information relayed 
to caregivers during this study will depend mostly on how it is cognitively appraised by the 
caregivers.  Any given person may portray differing efficacy expectations when facing 
different challenges.  There is no method of controlling this aspect and it is difficult to 
continuously monitor levels of SE.  Likewise it is correct to expect intensity of action and 
persistence to vary with the strength of PSE.  As different individuals have encountered 
differing levels of efficacy-influencing situations, any new source of information will impact 
subjects uniquely100.  For example,   there are many levels of visual impairment.  Not all are 
treated with the same pair of spectacles.  However visually correcting spectacles will have 
some effect on all individuals.  In a similar sense there are many levels of SE and whilst all 
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individuals cannot be treated by the same intervention, it will influence all individuals to 
some degree100.  The CLCF-Q and the feedback will work in the same way that training 
wheels do when a child is learning to ride a bike.  It offers guidance and help teaching the 
caregiver how to face and overcome challenges until they no longer require the help.  The 
healthcare team should serve as motivators and guides and the CLCF-Q allows for this109.  
Using the CLCF-Q we should aim to reinforce the core belief that the caregiver has the 
power and control to produce the desired effects in any given situation.  Caregivers need to 
receive honest feedback concerning their performance104.   
‘No psychological factor or any other factor for that matter ever bears an invariant relation 
to human behaviour104.’ 
Natural behaviour is adaptive and anticipates control and motivation.  It is guided by goals 
and encouraged by the goal seeking process109.  Humans are proactive, aspiring towards 
targets and not just reactive.  As actions are rewarded this behaviour promotes re-action and 
further attempts100 137.  Thus caregivers not only plan and fore think their actions; they self-
regulate them.  They adopt personal standards and monitor and regulate their actions to 
challenges through self reactive influence.  However, self regulation of learning through 
performance and error correction is a prolonged drawn out process121.  
As the demand on a primary caregiver increases the SE tends to automatically decrease.  
They tend to move their focus towards negative aspects of a challenge and personal 
deficiencies. Ideally, as the state of the patient’s disease declines the persistence of the 
primary caregiver should increase and a favourable increase in SE would be welcomed.  
Beliefs regarding competency have varied but strong effects on the caregiver.   
The two components of motivation are activation and persistence.  Motivation requires a 
cognitive source of information consisting of goal setting and self evaluation.  This is what 
the CLCF-Q aims to do107 109.  Self prescribed goals are more effective than goals set by 
others109.  To establish consistent optimal performance one must possess the necessary skills 
required and a high level of SE.  The intervention we propose presents opportunities to 
develop both these skills and practice them.  
Lastly, SE is an important construct in improving our understanding of normal reactions to 
challenging stressors.  It is also worth noting that environmental factors are processed and 
transformed by caregivers and there worth depends on how the information is cognitively 
appraised hence they are other factors which need to be considered131. 
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Chapter Three 
Does the introduction of a parent reported outcome 
measure influence the self efficacy of caregivers of 
children with cystic fibrosis?  
__________________________________________________________________________ 
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5.1. Introduction 
 
CF is the most prevalent, autosomally recessive inherited, life shortening disorder in the 
Caucasian population40 75.  It is estimated that there are over 10 million carriers of the gene 
worldwide and 1 in 2500 live births are affected in the normal population54 74.   
As a result of recent advances in medical care the median age of survival has risen from 2 
years of age in 1938 to over 50 years of age74.  However, the daily life prolonging treatment 
involved is expensive, intensive and time consuming.  This can be a great burden on the 
caregiver. 
Paediatric medicine aims to improve the patient and their caregiver’s global QOL where 
possible alongside stopping or slowing down disease progression.  Measuring the impact of 
the chronic illness on these patients is becoming increasingly important.  Three decades ago 
the WHO released a definition for health, 
“a state of complete physical and social well being, not just the absence of disease65.” 
Consequently, time and resources have been allocated to ensure a good standard of life is 
achieved and over the past 2 decades numerous tools have been proposed to measure QOL.  
Measuring QOL is a method of subjectively evaluating the impact of chronic disease on a 
patient’s ADL and global well being.  QOL is, “a dynamic psychological construct, which 
describes the subjective health perceptions of the patients independently of objective health 
parameters66” and it fluctuates over time and disease progression. 
Over the past 25 years PtROM have become increasingly important in influencing treatment.  
A PtROM is, 
“A measure of a patient’s health status, elicited directly from the patient, that assesses how 
the patient feels and functions with respect to his or her health condition67.” 
Measures range from an item rating a single symptom to a multi-system analyses looking 
into the global HRQOL of the patient.  HRQOL measurement in CF allows the inclusion of a 
patient’s perspective.  It is a multidimensional construct comprised of the domains of 
physical functioning, social functioning and emotional and psychological functioning.  
Together they give an overall picture of the disease state incorporating otherwise untested for 
states such as anxiety and depression68.  Although previous studies have almost perfected the 
use of PtROM and HRQOL measurements, the exact use of this information and direct 
impact on the patient and their caregiver has had relatively fewer investments.  The affect of 
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these interventions on the patient’s further treatment or QOL remains unknown.  Studies 
have identified a need to measure the caregivers QOL.  Caregiver QOL directly influences 
the patient’s disease management83 138.   
Working with parents a PROM called the CLCF-Q was developed.  Its aim was to measure 
the burden of care on everyday living for caregivers of patients with CF.  This study will 
explore the use of this measure in a clinical setting; the CF annual assessment process.  The 
study will look at how this tool could be used to increase the caregiver’s SE in relation to 
facing the challenges of living with CF.  PSE is, 
”the expectation of personal success in a given situation102.” 
Bandura introduced his works on, ‘Self Efficacy,’ in 1977 paving the way for a new field of 
interest100-101. The concept of measuring SE first came to light in 1979.  Matthias Jerusalem 
and later Professor Ralf Schwarzer discussed how PSE reflected on optimistic self belief and 
is required to facilitate goal setting and persistence in everyday activities122.  Human 
behaviour is generally developed through careful modelling techniques.  Initially one may 
observe and follow others or follow instructions103.  Later one will learn from others or one’s 
own mistakes allowing for self corrective adjustments until the technique is refined to a 
suitable standard100.  Without PSE or with a low PSE, the task is seen as too great a 
challenge and can sometimes be avoided or performed with no intent to succeed102.  Four 
main sources of information alter PSE.  These are; performance accomplishments, 
physiological states, vicarious experience and verbal persuasion101.  Introducing the CLCF-Q 
with a feedback system, may influence the SE of caregivers by utilising the concepts of 
performance accomplishments and verbal persuasion.   
Studies have shown that an increase in PSE could directly correlate with and improve 
performance and success rate103.  A person’s PSE dictates their behaviour, choice of 
activities, effort expenditure, perseverance, coping efforts and will to face challenges100.  
Caregivers may be more likely to take on challenging tasks with a belief of succeeding if 
they have a higher level of SE.  They are also more likely to confidently make decisions 
about the treatment their child receives.  This possible increase in SE may also correlate with 
their perception of control, improving the patient and their caregivers global QOL overall.   
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5.2. Objectives 
 
5.2.1. Aims 
 
The aim of this pilot study was to explore the feasibility and benefits of using the CLCF-Q 
measure in a clinical setting.  The impact of using the CLCF-Q on the SE of caregivers was 
assessed.  Semi-structured interviews were undertaken with a caregiver to inform the results 
qualitatively.  Data from this study will be used in power and sample size calculations for a 
larger multicentre study. 
 
5.2.2. Hypothesis 
 
It is hypothesised that incorporating the CLCF-Q into the annual assessment process and 
offering subsequent feedback will have a positive influence on the SE of caregivers. 
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5.3. Methodology 
 
5.3.1. Administrative Organisation 
 
This single centre study was carried out at the CF outpatients unit at Alder Hey Children’s 
Hospital.  All participants were approached, recruited and seen at the outpatient department.  
The study was affiliated with the Institute of Child Health, University of Liverpool.  It was 
co-sponsored and funded by both parties.  The study was also funded by the Alder Hey CF 
Trust Fund.   
 
5.3.2. Ethical Approval 
 
Ethical approval was granted in full from both the NHS Research and Development 
Committee and the NHS Research Ethics Committee.  The study was also approved by the 
University of Liverpool Research Governance Officer.  This study is part of a series of 
studies conducted to contribute to the validation of the CLCF-Q as a clinical tool. 
 
5.3.3. Study population  
 
Participants consisted of both genders with no restriction on age and background.  They were 
selected on the basis of the inclusion criteria.  In each caregiver/child dyad the primary 
caregiver was invited to participate in the study.  It is not assumed that this would be the 
mother in the family; parents were asked to decide who is most suitable themselves. 
 
5.3.3.1. Selection Procedure 
 
The recruitment was headed by the research team. Prospective participants were determined 
using data available on their child’s information sheet in the hospital database.  They were 
matched according to the inclusion and exclusion criterion below to determine their 
suitability. 
 
5.3.3.1.1. Principal Inclusion Criteria 
 
The principal inclusion criterion was; 
 
1 The caregiver must have a child diagnosed with CF. 
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2 The diagnosis of CF must have been made at least one year ago. 
3 The child must be registered as a patient at Alder Hey Children’s Hospital. 
4 The child must be between 1 and 13 years of age as the CLCF-Q is only validated 
for use with children between this age range. 
5 The caregiver must have a reasonable understanding of the study, understand what is 
involved of them and be competent enough to refuse participation. 
 
5.3.3.1.2. Principal Exclusion Criteria 
 
The principal exclusion criterion was; 
 
1 Caregivers or children with physical or mental disabilities which prohibit them from 
participating in the study successfully. 
 
5.3.3.2. Recruitment Procedure 
 
Following verbal consent, prospective participants were approached by the researcher during 
an outpatient clinic appointment and invited to partake in the study.  They were informed 
about the study and provided with an invitation letter and participant information sheet to 
take home and study at their own convenience.  Participants were given the option and time 
to approach the research team or an independent party regarding any queries.  There was no 
public advertisement of the study. 
At the annual assessment appointment, caregivers were reminded of the study and given 
another opportunity to read the participant information sheet, as well as make any concerns 
known.  Following voluntary, informed, written consent participants were recruited onto the 
study.   
 
5.3.3.3. Randomisation procedures 
 
On a randomised basis participants were allocated to 2 groups; a control and an intervention 
group.  Participants were randomised in groups of 10 as recruitment rate was unclear.  The 
participants were randomised immediately following consent and the Sealed Envelope© 
process was employed.  To maintain objectivity they were allocated by an independent party.   
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5.3.4. Experimental Design 
 
A randomised controlled non-blinded intervention pilot study supported by qualitative data 
was carried out between April 2010 and August 2010 at a single centre.  All participants 
were asked to complete a selection of questionnaires at 2 time points during their child’s 
annual assessment process.  The outcome measure in the study was determined using the 
Cystic Fibrosis Self Efficacy-Questionnaire (CFSE-Q).   
 
5.3.4.1. Narrative Interviews 
 
A diagnosis of CF affects all areas of family dynamics65.  Whilst the value of science on the 
prognosis of a child’s health and QOL cannot be undermined the value of congruent 
psychological input must be considered.  Direct feedback from the child and their caregiver 
regarding a treatment is invaluable.  Whilst the value of quantitative methods and results in 
research are clear the concepts put forward by qualitative data must not be undervalued.  
This study centres on two majors concepts; improving SE using PROM and the effect of SE 
on QOL.  Qualitative data are essential in these cases.  In practice a change in SE can be 
mapped and identified statistically however if the participant does not feel that this change is 
a positive one then compliance is unlikely.  Furthermore, if the intervention is disconcerting 
compliance is affected further.  Thus, qualitative data are invaluable in our study.  The mixed 
methodological approach is a real strength in this study and the quantitative and qualitative 
components support each other. 
 
The aim of the qualitative component of this project was to add support to the quantitative 
data as well as forming standalone conclusions.  The three forms of qualitative methods 
considered are; observations, interviews and focus groups.  To extract individual caregiver 
opinions textually in a non-scrutinised and unbiased environment interviews were deemed 
most appropriate.  The quantitative methods were employed to confirm the hypothesis and 
present statistically steady evidence.  The qualitative data was initially presented to explore 
the role of the annual assessment.  The anticipated scope was flexible.  This was the primal 
attraction to qualitative data.  This played a role in the type of interview carried out and 
stringent group interviews were discouraged. 
 
Quota sampling which is similar to purposive sampling and involves identifying participants 
according to set criterion to fulfil set quotas was the most ideal method.  The criterion 
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included; 1) early and late diagnosed children, 2) different family dynamics i.e. families with 
siblings and without and 3) both male and female caregivers where possible.  This criterion 
was set as a guide.  An equal number of participants from both the control and intervention 
groups will be sought.  The interview process required the caregivers to consider the study in 
its entirety.  Each participant had a unique study timeline projected along their pre-dated 
appointment times.  This was designed to have minimal bearing on their already busy 
schedules.  At this early stage in the study only 9 caregivers had completed both phases 1 
and 2 (ncontrol = 4, nintervention = 5).  Of this subgroup only 1 caregiver was scheduled for a 
further appointment thus able to participate in an interview.   
 
A semi-structured interview was carried out with 1 participant.  For ease it was carried out in 
a designated interview room on hospital premises.  The interview focussed on a challenging 
period the caregiver had faced over the last year, how this challenge was approached by the 
caregiver, family and the healthcare team and their views on how these challenges were 
managed as a whole.  Opinions and thoughts were sought on the study intervention and the 
value of the CLCF-Q as a key data transfer tool between the caregiver and the CF team.  The 
interview lasted 30 minutes.   
 
Data collection involved full manual transcription of the audio taped interview and where 
possible included body language and demeanour.  All correspondence between the research 
team and the participants also contained space for further feedback and queries.  This data 
was also collated fully and maintained in the participants own words.  The transcribed 
version was made available to the participant for approval of the contents.  Only then were 
the contents analysed.  The interview was interpreted through narrative analysis.   
 
Narratives are not accurate reflections on past experiences.  They are subjective accounts of 
what the storyteller perceives as significant details139.  The objective of the interview was to 
ascertain what the caregiver believed to be important in the approach to their child’s 
treatment.  The role, involvement and relationship with the CF team were of particular 
interest.  Could a PROM aid this role?  Approach to narrative data analysis was primarily 
thematic analysis however incorporated structural analysis.  Emphasis was placed on the 
content of the narrative in an attempt to source out themes.  Common themes will eventually 
be identified throughout all the narratives once data collection is completed.  Structural 
analysis plays a role in interpreting where the storyteller places emphasis.  This is important 
in identifying issues important to the caregiver. 
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Accounting for validity in qualitative methods is very difficult.  Slight environmental 
changes including interviewer bias can restructure data entirely.  The open nature of 
narratives is both its strength and a weakness.  Whilst it allows the storyteller to lead the data 
it also makes it increasingly difficult to reproduce and can sometimes lead to a number of 
interpretations.  Interviews will however, be semi structured with a clear direction of 
movement.  The main limitation at present is the lack of participants at Phase 3 of the study.  
This will be addressed as the study progresses.  All transcripts will be readdressed to the 
participant prior to analysis in the raw transcript format for permission.  This also acts as 
respondent validation increasing the validity of any individual piece of data.   
 
5.6.5. Study Intervention  
 
All participants completed a CFSE-Q both at the start and at the end of the study.  This 
captured their PSE at 2 time points before and after their child’s annual assessment.   
Participants in the intervention group were also introduced to the CLCF-Q during their 
child’s annual assessment appointment.  At the next outpatient appointment all participants 
received the results of their child’s annual assessment.  The intervention group also received 
their copy of the CLCF-Q which was accompanied with feedback.  This process involved the 
participant completing a self feedback form which asked them to predict their results of the 
CLCF-Q.  This was followed with a formal feedback form which concluded with the 
accurate results of their CLCF-Q.  Any issues which arose from the CLCF-Q were discussed 
with the researcher and advice was given regarding which member of the CF team could 
offer help.  Participants were left to complete their appointment.  All participants later 
received a letter outlining the results of the annual assessment.  For participants in the 
intervention group this was followed by a summary of the results of the CLCF-Q.  Following 
completion of the study all participants were given the opportunity to comment and feedback 
on the study.  All parties involved with the study will also be offered a lay report. 
 
 
 
 
 
 
 
 
 
 
65 
 
 
 
5.3.6. Study Intervention Points 
 
Table 12 - Study Intervention Points 
 
Phase Intervention Time Point Group Duration 
Phase 1 Invitation to 
participate 
Outpatient clinic 
appointment 1 
All participants 5 minutes 
Registration of 
interest and consent 
Annual assessment 
appointment 
All participants 10 minutes 
CFSE-Q (baseline) 
Annual assessment 
appointment 
All participants 4 minutes 
CLCF-Q 
Annual assessment 
appointment 
Intervention Group 30 minutes 
Phase 2 Feedback from 
CLCF-Q 
Annual assessment 
appointment 
Intervention Group 30 minutes 
CFSE-Q (endpoint) 
Outpatient clinic 
appointment 2 
All participants 4 minutes 
Phase 3 Semi structured 
interview 
Outpatient clinic 
appointment 3 
Selected 
participants 30 minutes 
 
 
5.3.7. Interview Schedule 
 
Meeting 1 - Last Routine Cystic Fibrosis Outpatient’s Clinic, prior to the Annual 
Assessment 
 
Prospective participants were informed about the study and invited to participate.  They were 
given a copy of the, participant information sheet with a covering letter to take away and 
read in their own time.  Details regarding researchers and an independent contact were 
included to answer any queries. 
 
Meeting 2 - Annual Assessment Appointment 
 
Prospective participants were given an opportunity to discuss the study and make any 
necessary queries about the study and their involvement.  Informed voluntary consent was 
taken in writing by the research team.  All participants were asked to complete the CFSE-Q 
taking no longer than 4 minutes.  Following the successful completion of the CFSE-Q 
participants in the intervention group only were asked to complete the, CLCF-Q.   Patients 
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and their caregiver were then left to continue with their annual assessment appointment.  
They were offered as much time as they required completing the CLCF-Q though the 
recommended time for completion was 30 minutes.  The annual assessment appointments 
begun between 08:30 and 09:30 and lasted up to 3½ hours.  The completed CLCF-Q was 
collected at the end of the appointment. 
 
Meeting 3 - Next Routine Cystic Fibrosis Outpatient’s Clinic, post Annual Assessment  
 
Participants from the intervention group were asked to complete the Self-feedback Form 
predicting how the CLCF-Q would score them on 17 specific areas.  This was followed by a 
detailed, colour coded illustration of their actual results from the CLCF-Q measure.  They 
were given the guidance, choice and opportunity to discuss their results with the researcher 
and different members of the CF team.  Participants were then given feedback from the 
annual assessment.  Following the clinic a summary of their annual assessment findings and 
any changes made were detailed in a letter and sent to all participants in the study; this is the 
norm.  Participants in the intervention group were also sent copies of the Self-Feedback 
Form and an accurate Feedback Form from the CLCF-Q. 
 
Meeting 4 – Second Routine Cystic Fibrosis Outpatient’s Clinic, post Annual 
Assessment  
 
Participants were asked to complete a second CFSE-Q.  
 
Meeting 4/5 - Interviews 
 
A further meeting was arranged with selected willing participants from across the study.  
This meeting took place after clinic visits and was in the form of individual semi-structured 
interviews.  Participants were given an opportunity to discuss their thoughts and experiences 
and again address any concerns they may have had. 
 
5.3.8. Scoring the Challenges of Living with Cystic Fibrosis-Questionnaire 
 
The CLCF-Q consists of 10 domains and 62 items.  Items to be equated numerically are 
scored on 4-point and 5-point Likert scales and yes-no format.  A further 3 items require 
written input; these items.   
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Items may be positively or negatively marked.  Answers are consolidated to sub-domains for 
feedback purposes.  To illustrate the spread of opinions and feedback from caregivers in the 
intervention group items were equated and tabulated. 
5.3.9. Scoring the CFSE-Q 
 
Originally designed as a 10 item questionnaire where each item is marked on 4-point Likert 
scales, the GSE-S yields scores between 10 and 40 where 40 is the highest.  The adapted 
model for this study, the CFSE-Q, includes the addition of 4 items specific to CF care.  
These follow the same trend in scoring and yield a final score of 56.  For the purpose of this 
study scores were initially presented using just the validated items.  The non-validated items 
are later introduced generating SE specific to caring for a child with CF. 
 
5.3.10. Statistical Analysis 
 
Due to time constraints, this study formed only part of the pilot study.  Complete data was 
collected from a small number of participants (n=9).  This study was not adequately powered 
to detect the difference between the groups, hence hypothesis testing was inappropriate.  The 
results of this study are descriptive.  The results of the CLCF-Q and CFSE-Q are tabulated as 
descriptive data.  The baseline and endpoint spread and change in SE scores are also 
described as established from the CFSE-Q.  Correlation between pre-annual assessment and 
post-assessment SE was evaluated in both the control and intervention groups.  These initial 
results do suggest a positive trend in the intervention group. To assess the validity of these 
claims, the full sets of data from the entire study population (n=44) must be collated and 
analysed. 
 
The reliability and validity of the questionnaires, the CLCF-Q and CFSE-Q have been shown 
in previous studies96 122.  As the validity of the questionnaires is already known it is assumed 
that the recorded changes in SE are valid.  The reliability of the results of this study however, 
is difficult to anticipate at this early stage.  Confounding factors such as interviewer bias and 
external changes may have contributed to the SE of the caregiver, i.e. issues at home.  To 
determine the reliability of the full dataset the confounding factors will have to be accounted 
for.   
 
The pilot study is due for completion in April 2011.  When the full set of data has been 
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collected the results will be used to inform power calculations and establish the sample size 
required for a large multicentre study.  A minimal clinical and statistical important difference 
in SE score will also be determined. 
__________________________________________________________________________ 
 
Chapter Four 
Results 
__________________________________________________________________________ 
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5.4. Results 
 
The results described are preliminary results from the initial recruitment of the pilot study.  
The data are small in numbers and statistical analyses lack power and validity.  Thus power 
and sample size calculations were omitted.  The data displayed are descriptive in nature and 
depicts the data at a time point early in the study temporal.  Further data will be collated as 
the study progresses and analysed accordingly.
The different elements of the study will be analysed separately.  The data collated from the 
CFSE-Q is described and graphed descriptively.  The qualitative element adapted from the 
CLCF-Q is illustrated and analysed further in the company of the written information and 
feedback from participants including the interview. 
 
5.4.1. Population Data 
 
Participants in the study were selected on the basis of their child; a patient with CF.  At the 
time the study began 82 patients were registered at Alder Hey Children’s Hospital on the CF 
register not including, patients registered to peripheral clinics.  Of the 82 patients, 24 did not 
fulfil the inclusion criteria; 2 were too young and 22 were too old.  A further 3 patients were 
excluded from the study due to social circumstances.  Of the remaining, 2 more were 
excluded.  In both cases there was more than one sibling in the caregivers/child dyad thus 
only one patient was included in the study.   
Of the remaining 53 patients 9 are yet to be approached.  Forty four families have been 
formally approached and presented with the participant information sheet.  Due to the 
timeline outlined participants can only commence the study during their annual assessment 
appointment.  The annual assessment takes place once a year at different times of the year 
for different patients.  To date, of the 44 approached, 21 have had their annual assessment 
since April 2010.  Three patients were lost at follow up due to appointment cancellations and 
changes.  Eight patients were randomised to the control group and 10 to the intervention 
group.   
There are 3 phases to the study.  Phase 1, determines the caregiver’s baseline SE score and 
takes place at the annual assessment appointment lasting the duration of the appointment.  
Phase 2 commences at the following outpatient clinic appointment where feedback from the 
annual assessment is given and continues to the next appointment where endpoint SE scores 
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are determined.  Phase 3 involves a selection of participants from both groups for narrative 
based semi structured interviews.   
The study is ongoing and recruitment and population records will alter accordingly. 
 
 
 
Figure 5.1: Study sample to date, August 2010 
 
 
Participant characteristic data at baseline is detailed in the table below.  Expectedly, the 
majority of caregivers were female.  Only 5.9% were in receipt of help with childcare.  The 
 
Caregivers approached 
napproached = 21 
 
Written consent 
 
N = 18 
(ncontrol = 8, nintervention = 10) 
Completed Phase 1 
(annual review) 
nphase 1 = 18 
(ncontrol = 8, nintervention = 10) 
Completed Phase 2 
(feedback + appointment) 
nphase 2 = 9 
(ncontrol = 4, nintervention = 5) 
 
Lost at follow-up 
nlost = 3 
Completed Phase 3  
(interview) 
nphase 3 = 1 
(ncontrol = 0, nintervention = 1) 
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ratio of female:male children was 7:11  Though patients were not stratified prior to 
randomisation, the age and sex distribution of the children was impartial. 
 
 
Table 13 – Caregiver and Child Characteristics at Baseline 
 
Characteristic Control Group 
Intervention 
Groups 
Total 
Relationship to Child    
Mother  7 (38.9%) 10 (55.6%) 17 (94.4%)  
Father 1 (5.6%) 0 (0%)  1 (5.6%) 
Child care support?     
Yes 0 (0%) 1 (5.6%) 1 (5.6%) 
No 8 (44.4%) 9 (50.0%) 17 (94.4%) 
Sex age of child     
Female 3 (16.7%) 4 (22.2%) 7 (38.9%) 
Male  5 (27.8%) 6 (33.3%) 10 (55.6%) 
Mean age of child     
1 - 4 0 (0%) 0 (0%) 0 (0%) 
5 – 9 3 (16.7%) 4 (22.2%) 7 (38.9%) 
9 - 13 5 (27.8%) 6 (33.3%) 10 (55.6%) 
 
 
5.4.2. Quantitative Data 
 
5.4.2.1. Cystic Fibrosis Self Efficacy-Questionnaire 
 
5.4.2.1.1. Item Analysis 
 
5.4.2.1.1.1. Analysis of Validated Items in the CFSE-Q 
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Table 14 - Baseline Scores of Previously Validated Items on the CFSE-Q  
Item 
Not at all  
true 
Hardly 
 true 
Moderately  
true 
Exactly  
true 
Group 
1 
I can always manage to solve difficult 
problems if I try hard enough 
- - 6 2 Control 
- - 5 5 Intervention 
0 (0%) 0 (0%) 11 (61.1%) 7 (38.9%) Total 
3 
If someone opposes me, I can find the 
means and ways to get what I want 
- 1 6 1 Control 
1 1 6 2 Intervention 
1 (5.6%) 2 (11.1%) 11 (61.1%) 3 (16.7%) Total 
4 
It is easy for me to stick to my aims and 
accomplish my goals 
- - 4 4 Control 
- 1 7 2 Intervention 
0 (0%) 1 (5.6%) 11 (61.1%) 6 (33.3%) Total 
5 
I am confident that I could deal efficiently 
with unexpected events 
- 1 3 4 Control 
- - 6 4 Intervention 
0 (0%) 1 (5.6%) 9 (50.0%) 8 (44.4%) Total 
6 
Thanks to my resourcefulness, I know how 
to handle unforeseen situations 
- 1 2 5 Control 
- - 4 5 Intervention 
0 (0%) 1 (5.6%) 6 (33.3%) 10 (55.6%) Total 
8 
I can solve most problems if I invest the 
necessary effort 
- - 3 5 Control 
- - 7 3 Intervention 
0 (0%) 0 (0%) 10 (55.5%) 8 (44.4%) Total 
10 
I can remain calm when facing difficulties 
because I can rely on my coping abilities 
- 2 2 4 Control 
- 1 7 2 Intervention 
0 (0%) 3 (16.7%) 9 (50.0%) 6 (33.3%) Total 
11 
When I am confronted with a problem, I 
can usually find several solutions 
- 2 3 3 Control 
1 1 6 2 Intervention 
1 (5.6%) 3 (16.7%) 9 (50.0%) 5 (27.8%) Total 
12 
If I am in trouble, I can usually think of a 
solution 
- - 5 3 Control 
- - 7 3 Intervention 
0 (0%) 0 (0%) 12 (66.7%) 6 (33.3%) Total 
14 
I can usually handle whatever comes my 
- - 3 5 Control 
- - 7 3 Intervention 
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way 
0 (0%) 0 (0%) 10 (55.6%) 8 (44.4%) Total 
Table 15 - Endpoint Scores of Previously Validated Items on the CFSE-Q  
Item 
Not at all  
true 
Hardly 
 true 
Moderately  
true 
Exactly  
true 
Group 
1 
I can always manage to solve difficult 
problems if I try hard enough 
- - 2 2 Control 
- - 2 3 Intervention 
0 (0%) 0 (0%) 4 (44.4%) 5 (55.6) Total 
3 
If someone opposes me, I can find the 
means and ways to get what I want 
- 1 1 2 Control 
1 2 2 - Intervention 
1 (11.1%) 3 (33.3%) 3 (33.3%) 2 (22.2%) Total 
4 
It is easy for me to stick to my aims and 
accomplish my goals 
- - 3 1 Control 
- 1 3 1 Intervention 
0 (0%) 1 (11.1%) 6 (66.7%) 2 (22.2%) Total 
5 
I am confident that I could deal efficiently 
with unexpected events 
- - 2 2 Control 
- - 1 4 Intervention 
0 (0%) 0 (0%) 3 (33.3%) 6 (66.7%) Total 
6 
Thanks to my resourcefulness, I know how 
to handle unforeseen situations 
- 1 - 3 Control 
- - 3 2 Intervention 
0 (0%) 1 (11.1%) 3 (33.3%) 5 (55.6) Total 
8 
I can solve most problems if I invest the 
necessary effort 
- - 3 1 Control 
- - 1 4 Intervention 
0 (0%) 0 (0%) 4 (44.4%) 5 (55.6) Total 
10 
I can remain calm when facing difficulties 
because I can rely on my coping abilities 
- 1 1 2 Control 
- - 3 2 Intervention 
0 (0%) 1 (11.1%) 4 (44.4%) 4 (44.4%) Total 
11 
When I am confronted with a problem, I 
can usually find several solutions 
- 1 1 2 Control 
- 1 2 2 Intervention 
0 (0%) 2 (22.2%) 3 (33.3%) 4 (44.4%) Total 
12 
If I am in trouble, I can usually think of a 
solution 
- - 2 2 Control 
- - 2 3 Intervention 
0 (0%) 0 (0%) 4 (44.4%) 5 (55.6) Total 
14 
I can usually handle whatever comes my 
- - 2 2 Control 
- - 2 3 Intervention 
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way 
0 (0%) 0 (0%) 4 (44.4%) 5 (55.6) Total 
 
Figure5.2: Self Efficacy Score at 
Baseline – Intervention Group 
 
 
Figure5.3: Self Efficacy Score at 
Baseline – Control Group 
 
 
Figure5.4: Self Efficacy Score at 
Baseline – Comparison 
 
 
Baseline SE across all participants who 
completed phase 1 only, ranged from 26 – 
39 (mean 32.9).  SE of participants in the 
control group who completed phase 1 
only, ranged from 26 – 37 (mean 33.6) 
whilst ranging 27 – 39 (mean 32.3) in the 
intervention group.  Baseline SE across all 
participants who completed phase 1 and 
phase 2 ranged from 26 – 39 (mean 30.8).  
SE of participants in the control group 
who completed phase 1 and phase 2 
ranged from 26 – 36 (mean 30.8) whilst 
ranging 27 – 39 (mean 30.8) in the 
intervention group. 
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Figure5.5: Self Efficacy Score at 
Endpoint – Intervention Group  
 
 
Figure5.6: Self Efficacy Score at 
Endpoint – Control Group 
 
 
 
Figure5.7: Self Efficacy Score at 
Endpoint – Comparison 
  
 
 
Endpoint SE across all participants ranged 
from 27 – 40 (mean 33.6).  SE in control 
group ranged from 27 – 40 (mean 33.5) 
whilst ranging 28 – 39 (mean 33.6) in the 
intervention group.  Non-validated items 
specific to CF care have not been included 
in final scores. 
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Figure5.8: Self Efficacy Score at 
Baseline and Endpoint – Intervention 
Group 
 
 
Figure5.9: Self Efficacy Score at 
Baseline and Endpoint – Control 
Group 
 
 
Figure 5.10: Self Efficacy Score at 
Baseline and Endpoint – Comparison 
 
 
The correlation between baseline and 
endpoint SE is closely matched in both 
control and intervention groups.  
However, non-validated items specific to 
CF care have been excluded from 
analyses. 
 
 
 
5.4.2.1.1.2. Analysis of Non-Validated Items on the CFSE-Q 
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Table16 - Baseline Scores of Non-Validated Items on the CFSE-Q  
Item 
Not at all  
true 
Hardly  
true 
Moderately 
true 
Exactly  
true 
Group 
2 
I face problems on a daily basis 
- 2 4 2 Control 
- 5 4 1 Intervention 
0 (0%) 7 (38.9%) 8 (44.4%) 3 (16.7%) Total 
7 
I do have the support I need to solve 
problems 
- 1 2 5 Control 
- 2 3 5 Intervention 
0 (0%) 3 (16.7%) 5 (27.8%) 10 (55.6%) Total 
9 
I can only solve a problem if I 
expected it to happen 
2 4 2 - Control 
4 3 - 3 Intervention 
6 (33.3%) 7 (38.9%) 2 (11.1%) 3 (16.7%) Total 
13 
I never feel my views are fully 
appreciated 
3 3 1 1 Control 
2 4 3 1 Intervention 
5 (27.8%) 7 (38.9%) 4 (22.2%) 2 (11.1%) Total 
 
Table 17 - Endpoint Scores of Non-Validated Items on the CFSE-Q  
Item 
Not at all  
true 
Hardly 
 true 
Moderately  
true 
Exactly  
true 
Group 
2 
I face problems on a daily basis 
- - 1 3 Control 
- 3 2 - Intervention 
0 (0%) 3 (33.3%) 3 (33.3%) 3 (33.3%) Total 
7 
I do have the support I need to solve 
problems 
- 1 1 2 Control 
- 1 - 4 Intervention 
0 (0%) 2 (22.2%) 1 (11.1%) 6 (66.7%) Total 
9 
I can only solve a problem if I 
expected it to happen 
1 1 2 - Control 
3 2 - - Intervention 
4 (44.4%) 3 (33.3%) 2 (22.2%) 0 (0%) Total 
13 1 - 2 1 Control 
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I never feel my views are fully 
appreciated 
2 2 1 - Intervention 
3 (33.3%) 2 (22.2%) 3 (33.3%) 1 (11.1%) Total 
Figure 5.11: Self Efficacy Score at 
Baseline and Endpoint – Intervention 
Group 
 
 
Figure 5.12: Self Efficacy Score at 
Baseline and Endpoint – Control 
Group 
 
 
 
Figure 5.13: Self Efficacy Score at 
Baseline and Endpoint – Comparison 
 
 
Figure 5.14: Self Efficacy Score at 
Baseline and Endpoint – Comparison 
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Baseline SE across all participants who completed phase 1 and phase 2 ranged from 36 – 53 
(mean 42.4).  SE of participants in the control group who completed phase 1 and phase 2 
ranged from 37 – 51 (mean 42.5) whilst ranging 36 – 53 (mean 42.4) in the intervention 
group. 
Endpoint SE across all participants ranged from 36 - 53 (mean 45.1).  SE in the control 
group ranged from 36 - 53 (mean 43.3) whilst ranging 39 - 52 (mean 46.6) in the 
intervention group.  Non-validated items specific to CF care have not been included in final 
scores. 
Following the inclusion of the non-validated items specific to CF care there is a clear 
difference in correlation between baseline and endpoint SE between the control and 
intervention groups.  The rate of change between baseline and endpoint SE is greater in the 
intervention group (Figure 5.13).  Figure 5.14 illustrates the rate of change following the 
removal of a possible outlier in the data.  The rate of change in Figure 5.14 is further 
apparent. 
5.4.2.1.2. Analysis of all Items in the CFSE-Q 
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Table 18 : Comparison of Consistent Changes in Items on the Cystic Fibrosis Self 
Efficacy-Questionnaire    
Item 
Change in 
Control Group 
Change in 
Intervention Group 
Type of Change 
1 
I can always manage to solve difficult 
problems if I try hard enough 
  Positive 
  Negative 
2 
I face problems on a daily basis 
  Positive 
  Negative 
3 
If someone opposes me, I can find the 
means and ways to get what I want 
  Positive 
  Negative 
4 
It is easy for me to stick to my aims and 
accomplish my goals 
  Positive 
  Negative 
5 
I am confident that I could deal efficiently 
with unexpected events 
  Positive 
  Negative 
6 
Thanks to my resourcefulness, I know how 
to handle unforeseen situations 
  Positive 
  Negative 
7 
I do have the support I need to solve 
problems 
  Positive 
  Negative 
8 
I can solve most problems if I invest the 
necessary effort 
  Positive 
  Negative 
9 
I can only solve a problem if I expected it to 
happen 
  Positive 
  Negative 
10 
I can remain calm when facing difficulties 
because I can rely on my coping abilities 
  Positive 
  Negative 
11 
When I am confronted with a problem, I 
can usually find several solutions 
  Positive 
  Negative 
12 
If I am in trouble, I can usually think of a 
solution 
  Positive 
  Negative 
13 
I never feel my views are fully appreciated 
  Positive 
  Negative 
14 
I can usually handle whatever comes my 
way 
  Positive 
  Negative 
Total 4 8 Positive 
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3 1 Negative 
In the control group there were several consistent changes in the CFSE-Q that were mirrored 
between participants.  These changes in SE occurred between the annual assessment 
appointment and the outpatient clinic appointment following feedback.  Consistent changes 
occurred in items 1, 2, 3, 6, 9, 11 and 13.   Item 1 increased in 50% of participants and 
related to their belief in their problem solving abilities. 
Item 1 - ‘I can always manage to solve difficult problems if I try hard enough.’ 
Item 3 which considered facing opposition, item 6 considering handling unforeseen 
circumstances and item 11 dealing with confrontational challenges all consistently increased 
in 50% of the participants.   
Item 3 - ‘If someone opposes me, I can find the means and ways to get what I want.’ 
Item 6 - ‘Thanks to my resourcefulness, I know how to handle unforeseen situations.’ 
Item 11 - ‘When I am confronted with a problem, I can usually find several solutions.’ 
Interestingly, despite these positive changes in SE participants also showed similar changes 
in items 2, 9 and 13.  These items are 3 of the 4 non-validated items that were included in 
our version of the CFSE-Q.  They were negatively marked on the 4-point Likert scale thus an 
increase in the scores would show a decrease in SE. 
Item 2 - ‘I face problems a daily basis.’ 
Item 9 – ‘I can only solve a problem if I expected it to happen.’ 
Item 13 - ‘I never feel my views are fully appreciated.’ 
Fifty percent of participants showed an increase in scores of items 2 and 9.  Seventy five 
percent showed an increase in item 13.  As these were negatively marked on the Likert scale 
an increase in the score translated to the statements being truer.  Thus some participants in 
the control group felt, that they faced more problems, found it harder to solve problems and 
most felt that their views weren’t fully appreciated following the feedback they received 
from the annual assessment compared to their baseline SE score.   
The intervention group portrayed consistent exaggerated changes in SE scores.  Item 1, 11, 
12 and 14 were increased in 40% of participants.  Items 5 and 8 were increased in 60% of 
participants.   
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Item 1 - ‘I can always manage to solve difficult problems if I try hard enough.’ 
Item 11 - ‘When I am confronted with a problem, I can usually find several solutions.’ 
Item 12 - ‘If I am in trouble, I can usually think of a solution.’ 
Item 14 - ‘I can usually handle whatever comes my way.’ 
Item 7, an additional non-validated item increased score in 60% of participants.  Item 13, 
also a non-validated item decreased in 40% of participants.  However it is negatively scored 
thus a decrease in score reflects an increase in SE.  However, item 3 which related to facing 
opposition decreased in 40% of participants.   
Item 7 - ‘I do have the support I need to solve problems.’ 
Item 13 - ‘I never feel my views are fully appreciated.’ 
Item 3 - ‘If someone opposes me, I can find the means and ways to get what I want.’ 
SE scores between baseline and endpoint remained consistent or increased across all 
participants in both groups.  There were no negative changes in overall SE score, determined 
using validated items, between time points.  The inclusion of non-validated items in 
assessment reveals a significant and consistent negative change in 3 of the 4 items in the 
control group in comparison to only one item in the intervention group.  This is further 
supported by the significant consistent increase in 8 of the 10 validated items in the 
intervention group compared to a consistent increase in only 4 items in the control group.
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5.4.3. Qualitative Data 
 
5.4.3.1. Challenges of Living with Cystic Fibrosis-Questionnaire  
Table 19 – Challenges of Living with Cystic Fibrosis-Questionnaire 
 
Item Subscale N 
Family Lifestyle 
Are you? 
Lone caregiver 2 (20%) 
With spouse 8 (80%) 
With family 0 (0%) 
How many children do you care for in your family? 
5 1 (10%) 
3 1 (10%) 
2 7 (70%) 
1 1 (10%) 
How many children with CF do you have living with you? 
2 2 (20%) 
1 8 (80%) 
How does your family divide childcare relating to CF? 
I do it all 4 (40%) 
I receive some help 6 (60%) 
How would you describe your general family 
lifestyle?   
Is it relaxed or stressed out? 
Stressed out 1 (10%) 
Sometimes stressed 5 (50%) 
Relaxed 4 (40%) 
Is it busy or laid back? 
Busy 6 (60%) 
Sometimes busy 3 (30%) 
Laid back 1 (10%) 
Do you work together or work 
as individuals? 
Work as individuals 1 (10%) 
Sometime work alone 3 (30%) 
Work together 6 (60%) 
Is it disorganised or organised? 
Disorganised 0 (0%) 
Sometimes disorganised 4 (40%) 
Organised 6 (60%) 
Do you have no fixed routines 
or fixed routines? 
No fixed routines 0 (0%) 
Sometimes have routines 5 (50%) 
Fixed routines 5 (50%) 
How well do you think you are juggling the demands of CF with the needs of 
your family? 
Great difficulty 1(10%) 
Marginal difficulty 4 (40% 
No difficulty 5 (50%) 
How well do you think your family as whole handles the challenges of CF? 
Great difficulty 3 (30%) 
Marginal difficulty 4 (40%) 
No difficulty 3 (30%) 
   
CF Background 
*All children were pancreatic insufficient 
Over the last two weeks, how has your child been? 
Unwell 0 (0%) 
A mixture 2 (20%) 
Mostly well 8 (80%) 
Has your child ever had a hospital admission? Yes 10 (100%) 
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No 0 (0%) 
85 
 
 
Child’s Character 
Please grade the following statements 
My child makes more demands 
on me than I expected 
Agree 3 (30%) 
Sometimes 2 (20%) 
Disagree 5 (50%) 
My child goes to bed easily 
Agree 7 (70%) 
Sometimes 2 (20%) 
Disagree 1 (10%) 
My child sleeps throughout the 
night 
Agree 7 (70%) 
Sometimes 2 (20%) 
Disagree 1 (10%) 
It takes a long time for my child 
to settle with new routines 
Agree 1 (10%) 
Sometimes 4 (40%) 
Disagree 5 (50%) 
My child is easily upset by 
things generally 
Agree 3 (30%) 
Sometimes 4 (40%) 
Disagree 3 (30%) 
My child is very moody 
Agree 1 (10%) 
Sometimes 4 (40%) 
Disagree 5 (50%) 
My child reacts very strongly 
when something happens that 
s/he doesn’t like 
Agree 6 (60%) 
Sometimes 4 (40%) 
Disagree 0 (0%) 
    
Challenges to Family Life 
How supported do you feel by the following 
groups of people? 
Family members 
Not at all supported 3 (30%) 
Very supported 7 (70%) 
Friends 
Not at all supported 2 (20%) 
Very supported 8 (80%) 
Another parent whose child has 
CF 
Not at all supported 6 (60%) 
Very supported 4 (40%) 
CF team 
Not at all supported 0 (0%) 
Very supported 10 (100%) 
GP 
Not at all supported 2 (20%) 
Very supported 8 (80%) 
Pharmacy 
Not at all supported 1 (10%) 
Very supported 9 (90%) 
Caring for a child with CF can involve extra expense.  How difficult is it for 
you to manage this? 
Very difficult 1 (10%) 
Moderately 3 (30%) 
Not at all difficult 6 (60%) 
To what extent do you think CF has changed your work pattern? 
A great deal 8 (80%) 
Not at all 2 (20%) 
How often have you had a disturbed night’s sleep in the past 2 weeks? 
Frequent 1 (10%) 
Some 1 (10%) 
Few 8 (80%) 
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Hopes and Worries 
Some say that living with CF is like a balance 
of hope and worry: 
What hope do you have for your child?   
 
S/he will adjust well to 
secondary school 
Not hopeful 1 (10%) 
Hopeful 9 (90%) 
S/he will go on to higher 
education 
Not hopeful 1 (10%) 
Hopeful 9 (90%) 
S/he will have a job 
Not hopeful 2 (20%) 
Hopeful 8 (80%) 
S/he will have a family of 
his/her own? 
Not hopeful 4 (40%) 
Hopeful 6 (60%) 
S/he will continue to be as well 
as s/he is now? 
Not hopeful 3 (30%) 
Hopeful 7 (70%) 
There will be an advance in 
science that will help my child? 
Not hopeful 1 (10%) 
Hopeful 9 (90%) 
It is difficult to predict what the future hols in relation to CF.  To what extent 
does this uncertainty affect your family’s approach to life? 
A great deal 2 (20%) 
Moderately 4 (40%) 
Not at all 4 (40%) 
How much does the responsibility of looking after a child with CF affect you? 
A great deal 7 (70%) 
Moderately 1 (10%) 
Not at all 2 (20%) 
How much is your child’s height a worry for you? 
A great deal 2 (20%) 
Moderately 5 (50%) 
Not at all 3 (30%) 
How much is your child’s weight a worry for you? 
A great deal 2 (20%) 
Moderately 3 (30%) 
Not at all 5 (50%) 
How worried are you about a change in your child’s lung function? 
A great deal 6 (60%) 
Moderately 2 (20%) 
Not at all 2 (20%) 
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CF Routines 
How easy was it to establish the CF care routine after our child was diagnosed? 
Not at all easy 4 (40%) 
Moderately easy 4 (40%) 
Very easy 2 (20%) 
How much of a problem is it to manage the 
daily routine of CF now? 
Mealtimes 
A constant problem 4 (40%) 
Sometimes a problem 2 (20%) 
No problem 4 (40%) 
Digestion 
A constant problem 5 (50%) 
Sometimes a problem 3 (30%) 
No problem 1 (10%) 
Taking enzymes 
A constant problem 7 (70%) 
Sometimes a problem 3 (30%) 
No problem 0 (0%) 
Taking vitamins/oral antibiotics 
A constant problem 8 (80%) 
Sometimes a problem 2 (20%) 
No problem 0 (0%) 
Doing physiotherapy 
A constant problem 5 (50%) 
Sometimes a problem 2 (20%) 
No problem 3 (30%) 
Doing nebulised medications 
*n/a for 2 participants 
A constant problem 4 (50%) 
Sometimes a problem 2 (25%) 
No problem 2 (25%) 
With all the things that need to be done, it may be overwhelming at times.  
How true has this been for you over the last 2 weeks? 
Very true  4 (40%) 
Neutral 4 (40%) 
Not at all true 2 (20%) 
   
Community Support  
What quality of relationship do you have with your local GP/surgery? 
Not at all good 2 (20%) 
Moderately good 3 (30%) 
Very good 5 (50%) 
How helpful is your pharmacist? 
Not at all helpful 0 (0%) 
Moderately helpful 1 (10%) 
Very helpful 9 (90%) 
What sort of relationship do you have with your child’s 
minder/nursery/school? 
Not at all good 1 (10%) 
Moderately good 1 (10%) 
Very good 8 (80%) 
   
CF Clinic & Pharmacy Visits 
How long on average do you spend in the clinic at each appointment? 
4 hours 1 (10%) 
3 hours 7 (70%) 
2 hours 2 (20%) 
Please think about your last visit to the pharmacy.  How acceptable was the 
wait for medicine? 
Very unacceptable 3 (30%) 
Neutral 5 (50%) 
Very acceptable 2 (20%) 
How much information would you like to have from the CF team about your 
child’s condition or treatments? 
More information 3 (30%) 
The same as now 7 (70%) 
During hospital admissions patients and caregivers experience stress regarding staying in overnight, disruptions to family life, 
getting good care in hospital, getting the intravenous line in, child’s loneliness and communication with healthcare 
professionals. 
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Collective data from the CLCF-Q revealed 20% of participants were lone caregivers and 
90% of participants had between 2 and 5 children to care for.  In 20% of cases there were 2 
children in the caregiver/child dyad with CF furthermore 40% of primary caregivers 
admitted to doing all the work at home.  Resultantly, 10% acknowledged that their family 
lifestyle was stressed and a further 50% agreed that it was sometimes stressful.   
Understandably lifestyle was described as busy by 60% though 60% did also work together 
juggling the demands of CF as family.  Ten percent managed this with great difficulty; a 
further 40% managing with marginal difficulty.  Focussing on the family, 40% were coping 
with marginal difficulty whilst 30% of families handled challenges with great difficulty.   
All children in the intervention had experienced an inpatient stay at some point since 
diagnosis.  Clinically, 80% of children were described as mostly well over the fortnight prior 
to the annual assessment appointment.  As a result, the caregiver’s SE is expected to be high 
due to the lower levels of stress experienced when a child is well.  In general, when asked 
about their child’s character 30% were described as making more demands than expected 
and getting upset by things easily, a further 60% of children react very strongly when 
something happens that they don’t like.  Settling into routines, mood and sleeping were 
issues in a minority of cases but were generally well managed. 
Family and friends play a pivotal role in supporting caregivers in 70% and 80% of cases 
respectively.  Caregivers are not supported by other parents and families who are living with 
CF and a number of participants expressed concern regarding this.  Though ill advised due to 
cross infection parents would like to have contact with other parents in a similar situation.  
One caregiver stated that this lack of contact, “affected her a great deal.”  All participants felt 
particularly supported by the CF team and praised their efforts.  A small minority expressed 
further concern regarding their relationship with the GP and pharmacist.   
Caring for a child with a chronic disease can add to expenses.  Transport, parking, particular 
diet requirements, “cost of meals for parents during hospital admissions,” loss of income and 
adaptations made to the home all contribute to this.  Added expenses were an issue with 40% 
of caregivers and 80% admitted that they had sacrificed previous paid employment to care 
for their child.  As well as expense, time is another burden on the caregiver and family.  On 
average participants spent 2 hours 54 minutes in clinic every 10 weeks.  
Hopes and worries play a major role in managing CF.  Whilst most were hopeful regarding 
short term commitments including secondary school, higher education and finding 
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employment less were hopeful of long term prospects including their child raising a family 
of their own and continuing to be as well as they are now.  Ninety percent were also hopeful 
of an advance in scientific research dramatically changing their lives and all participants 
expressed the benefits of taking part in research.  This uncertainty regarding their future 
affected the families approach to life in 60% of cases and 70% of primary caregivers stated 
that the responsibility of looking after a child with chronic disease affected them greatly.  
Height, weight and lung function were amongst the main concerns, with the latter being a 
concern in 60% of cases. 
A diagnosis of CF results in substantial changes to family life.  Establishing a routine can be 
difficult and 40% described it as a difficult challenge.  Amid the concerns, were establishing 
mealtimes (40%) and promoting eating habits in particular taking enzymes (70%), vitamins 
and oral antibiotics (80%).  Doing physiotherapy and administering nebulised medications 
were constant difficulties for the participants.  During hospital admissions patients and 
caregivers experience stress regarding staying in overnight, disruptions to family life, getting 
good care in hospital, getting the intravenous line in, the child’s loneliness and 
communication with healthcare professionals.  Whilst all participants were very pleased with 
the service received from the CF team, 30% of caregivers expressed a need for further 
information about their child’s CF. 
The CLCF-Q not only allows caregivers to express concerns on certain areas it also enables 
them to voice their opinions on matters which concern them specifically. 
Question 28 enquired about the degree of change in work pattern attributed to being a 
primary caregiver.  One parent stated, “All my attention and energy goes on my child.”  
Caring for a child with CF is a full time commitment leaving little time for other ADL 
particularly employment.  Caregivers expressed feeling guilt and felt that they had to be at 
home for their child’s, “early years,” for several reasons.  A number of caregivers had, 
“changed to part time employment from full time” however this wasn’t always ideal.  One 
caregiver said, “Part time, annual leave used for appointments and illness.  Employers not 
helpful or colleagues when off with son.”  She went on to explain that her employers were 
not sympathetic to the needs of her child and requesting time off work to care for him was an 
awkward and unwelcomed gesture. 
During the multiple appointments the caregiver attends regarding their child’s CF, they are 
rarely asked how they are feeling and coping.  Parents seldom experience respite and so it is 
important that they recognise their own limits.   When asked how they detect their limits, a 
trend was apparent.  Many talked about feeling, more, “stressed and tired,” than usual.  
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References to mood and losing their, “temper easily” were also evident.  One caregiver 
wrote, “I may feel stressed and tearful for nothing at all” another added, “When we lose sight 
of ourselves and are overwhelmed.”  In the fortnight preceding the annual assessment 
appointment, 40% of the caregivers had felt frequently overwhelmed and a further 40% felt 
overwhelmed sometimes.   
Amongst other things caregivers balance their worries and hopes.  This affects both ADL 
and their approach to the future.  Worrying about how their child’s, “health will be in the 
future” and “about life expectancy,” was a common concern.  Caregivers expressed its 
impact on planning for the future and their outlook.  It is important to consider that co-
morbidities do exist within the CF population.  One caregiver stated “His CF/autism 
combined means we have to plan for the future more than other families.”   
For parents lung function results provide a good indication of how well their child is coping 
with CF.  Particularly at the annual assessment, caregivers felt that their main concern was 
the lung function result.  When asked about their main worry comments consistently 
followed a similar theme stating, “the chest,” “lung function decreasing slightly,” “lung 
damage that’s irreversible” and “that it will get worse and affect her breathing preventing her 
from doing her activities.”  General worries were described as the child not, “staying well,” 
“the unknown” and the need for routine and non routine admissions for interventions like, 
“needing a new port.”   
Coupled with the worries were similar hopes shared by caregivers.  These included a strong 
sense of hope for the future with the possibility of, “a cure,” hopes of, “treatments getting 
better,” and innovative “research.”  For the children who had been well, caregivers were 
subsequently hopeful that they would stay this well.  The care they received by the CF team 
also contributed to their hopes and happiness, I hope, “that she is happy and well looked 
after by the CF Team.”  Interestingly, even though the CLCF-Q enquired about the 
caregiver’s thoughts and abilities, one caregiver commented, “I am hopeful about my child’s 
ability to cope with CF.” 
5.4.3.2. Interview Analysis 
 
The aim of this study was to explore the practicality of measuring the SE of caregivers of 
children with CF., with an aim to improve SE using a simple feedback intervention 
employing the use of the CLCF-Q.  It was perceived that the variations in SE would be 
apparent. 
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In order to improve SE however, one must understand the determining factors.  It is 
important to understand the caregiver’s point of view.  How they recognise a challenge, their 
familial approach to the challenge and the meaning they associate with the CF team’s 
involvement are all key principles that need to be understood in order to improve a 
caregiver’s SE.   
During a semi-structured interview with a caregiver randomised to the intervention group 2 
challenges recently faced by the family were discussed.  The caregiver Mandy (pseudonyms 
have been applied throughout the script) was mother to 2 children with CF; a boy aged 12 
(Kevin) and a girl (Sarah) aged 10.  The father (James) remained in full time employment 
hence the participant was the primary caregiver at home.  When asked to think about a recent 
challenge Mandy began with,  
‘Change’ 
“Kevin started seniors and that was a bit of a challenge...Because at junior 
school, he was always given the right dose and we’d ask the staff to get them 
which all his friends new about anyway.  So that wasn’t a problem but in 
seniors I didn’t want to...  separate him from his friends for him to be going off 
somewhere.  I didn’t know whether he might not want to tell his friends that 
he’s got CF because it was only him going from juniors so he didn’t know 
anybody.  So I thought it would be up to him to tell them if he wanted to.  So he 
had them in his bag... and he often forgot, which led to him having a lot of pain 
and also when he needs to go to the toilet he’s got to go and, and they’re not 
allowed to go out in class so he has a toilet pass.  So really all the really it was 
going from the comfort of his junior school where everyone knew him to like a 
whole new um environment where he didn’t know anyone.  That was quite 
daunting.” 
The first challenge described is a uniformly experienced by all caregivers – It is a period of 
change.  A number of specific issues are addressed here; changing school is the primary 
challenge but within that are the issues of establishing relationships, medications, 
establishing routine and the disease management itself.  
Mandy talked about, Kevin establishing new relationships with his peers and placed 
emphasis on the effect of CF on their relationship.  She mentions the concepts of separation 
from friends and the difficulties of explaining CF.  The effect this challenge has on Kevin’s 
disease status is also discussed.   
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‘Independence’ 
“I didn’t know whether he might not want to tell his friends that he’s got CF 
because it was only him going from juniors so he didn’t know anybody.  So I 
thought it would be up to him to tell them if he wanted to.” 
The change in power over administering medication from school staff to Kevin and the 
option to tell his friends being left to him could be interpreted as a step towards establishing 
a degree of independence.   
‘Support’ 
The interview moved from the actual challenge itself to the management of the challenge 
and the first port of called was discussed. 
“Jenny!  I just phoned her!  Cos Jenny came to the Junior School when... 
because we moved when he started in Year 1.  He wasn’t in reception year.  We 
were living somewhere else.  So uh Jenny  came to that school when he started 
juniors and Jenny went to the senior school and talked to the teachers he was 
going to have and the head teacher... and that was a big help.  Jenny just 
takes... Jenny just takes the number of the school and arranges everything so I 
don’t even know when she’s going she just arranges it with the school.  So that 
just – that takes all weight.” 
Mandy seemed very pleased with the service and relieved that it was something less for her 
to worry about.  The interview progressed to a discussion about the study she had recently 
completed and her views on its worth as a permanent intervention in the annual assessment 
process.   
‘I don’t know any different’ 
The different components of the study were discussed and the value of each part of the 
intervention was considered. 
“Yes I think its... helpful, it’s helpful to pick up on anyone who’s having 
problems.  You know, you  sort of learn how to deal with the problems.  It would 
detect the different problems people are having.  Helpful to me as well because 
of the feedback you get from it and also it just makes you realise, because it’s 
something I’ve always done. Especially with me having two children with CF, I 
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don’t know any different.  I need stopping and actually think about how I am 
coping.  It didn’t take much time at all and I think any studies and research is a 
good thing. 
I think all of the study was important.  But I think the bit for me was... sort of 
how you’re dealing with things how you’re... especially the bit where, it says do 
you feel overwhelmed.  And I think the first time I did it, I said no, and then I 
think the second time I said yes because that was how I felt at the time, because, 
they both had symptoms and I go for so long with them being well and when 
they’re both not well at the same time it does overwhelm me a bit.” 
Mandy talked about the potential of the CLCF-Q to pick up on problems the caregiver is 
experiencing.   
‘I don’t normally get asked if I’m overwhelmed’ 
Her particular interest was in the feedback.  Seldom do caregivers get asked how they feel 
and yet it is their health which plays a pivotal role in that of their child’s.  Her reference to 
coping and dealing with the challenges, including the sense of feeling overwhelmed was 
characteristic of how the CLCF-Q portrayed the sample of caregivers in the intervention 
group.  They all expressed a concern over their ability to cope with challenges and felt that 
more emphasis on their health would be of benefit. 
“I don’t normally get asked if I’m overwhelmed.  Normally the focus is on the 
children not really us.  So it’s all about how they are.  I feel fine about it 
though... it would be helpful. It would.  But I also think that if I do have 
problems and I felt I couldn’t cope I do always ask for help.  I’d ask (laughter) 
Jenny and Elinor... again. There is always someone there.  There always has 
been.” 
‘We’ 
The next challenge reviewed concerns about Sarah.  She had recently been admitted to 
hospital.  Mandy’s role in the decision making process and her views on how the situation 
was handled were considered. 
“That came about when I went for the results of the annual review.  There were 
changes on the X-ray and Dr Southern sent her for a CT scan which showed 
that she had inflamed airways and then we decided to send her for a bronch.... 
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Bronchoscopy.  ...which we think we still hadn’t had the result.  But he seemed 
to think that it all pointed towards her growing pseudomonas.  Okay so now 
she’s in and having IVs three times a day and so hopefully I am going to learn 
how to do those.  So we can come home.  That’s my main worry, he’s not well at 
the moment and so I want to be there for him as well and my husband has got 
his own business so he has got to – he can’t have days off.  You know he’s 
trying to do the best he can in between work.  So I’m eager to get home and I 
can do the physio, she’s got a new physio regime to do.  So she has to do the 
physio and not just the acapello.  And nebuliser and inhaler.  So I’ve got to do 
all that as well as the IVs.  But I’d rather do that and be at home.  At least we’re 
there then – we’re at home.  We’re having a good sleep – so that’s what I’m 
hoping.  So she can come out on Friday.  So that within itself is quite a big 
challenge.” 
In contrast to the previous challenge this challenge was clinically orientated and focussed 
more on the topic of communication.  Emphasis was placed on the interaction between the 
CF team, specifically the consultant and Mandy as the primary caregiver.  This theme is 
apparent throughout the account.  X-rays are performed routinely at the annual assessment 
unless otherwise specified.  So this challenge arose as a consequence of the annual 
assessment.  References to other tests recommended by the consultant were made, however 
this was followed by a reference to, “we.”  The decision for the more intrusive test, the 
bronchoscopy was made by the consultant and Mandy.  This is followed on by the term, “he 
seemed to think,” which suggests that Mandy is not convinced.  Mandy returns to this 
comment later on in the interview.  The dialogue now focuses on the actual implications of 
the decisions made; the necessity of an admission, the need for intravenous antibiotics, the 
change in the physiotherapy routine and the addition of further treatment.  These are all 
added pressures for Mandy, “I’ve got to do all that.”  And this aspect is described as, “quite 
a big challenge.”  Whilst reference is made to James, her role as primary caregiver and his 
role as the main breadwinner are implied.  Throughout this section repeated references are 
made to, “home,” coupled with, “hoping.”  A positive outcome may be interpreted as being 
able to go home.  Evidence of the need to balance the care of both children is also apparent. 
‘treat you like a human being’ 
“Dr Southern showed me the CT scan and the biopsy as well.  He showed me 
that.  I feel as though he does treat you like a human being and tells you exactly 
how it is you know.  This is really important to me – to be involved with the 
care.” 
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Previously, Mandy had stated, “But he seemed to think that it all pointed towards her 
growing pseudomonas,” suggesting that the diagnosis was still unclear in her mind.  The 
dialogue above illustrates how the consultant improved her understanding further involving 
her in the decision making.  The significant phrase here is, “treat you like a human being and 
tells you exactly how it is.”  Caregivers want to be educated and need to be involved.  As 
shown by the results of CLCF-Q they welcome information and feedback thus keeping 
caregivers informed and involved must be a priority. 
“I do see the future positively now that it has been explained to me.  And I’ve 
seen the bronchoscopy and I’ve seen the... when they put the camera down and 
the secretions what she’s got to get up and the physio regime and and I am 
confident that we’ll get rid of the pseudomonas and keep her well.” 
Involving the caregiver in the decision making process helps empower them.  It enables them 
to gain a locus of control further supporting their confidence.  This is the aim of the CLCF-Q 
in this study. 
“I think when you understand a bit more.  When everything is explained to you 
and you understand it in your mind you can deal with things better.  It’s the 
unknown isn’t it that you that you worry about.” 
Essentially, a deeper understanding of the situation enables the caregiver to plan ahead when 
challenges manifest, further improving their coping abilities and SE. 
The conclusion will bring together the quantitative results described and the qualitative data 
from the CLCF-Q, the interview and the vignettes made on feedback sections.  Whilst 
qualitative data is listed in its original form the researcher’s interpretation adds further depth 
to the understanding.  
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5.5. Discussion 
 
This study builds on the results of a number of studies exploring the use of the CLCF-Q in 
clinical practice.  The CLCF-Q was initially developed to equate the burden of care on the 
caregiver.  This pilot study aimed to explore the feasibility of integrating the CLCF-Q into 
the annual assessment process in CF care.  The effect on the SE of caregiver’s of children 
with CF was of particular interest.  To determine the impact of the PROM on the SE of 
caregivers, a SE-measure specific to CF care was introduced; the CFSE-Q.  Qualitative 
methods were also applied to support the results and gain an understanding of challenge 
management; how the caregiver deals with the everyday challenges of living with a child 
with CF brings to the family140-141.  Data collected to date forms part of the information 
required in this pilot study to allow for power and sample size calculations.  The remainder 
of the pilot study is due for completion in April 2011.   
The role of the primary caregiver is complex and multidimensional.  It is subject to change in 
response to the child’s disease state and treatment demand138 142.  Caregivers face complex 
challenges on a daily basis and adapt to normalise these situations111.  Challenges are faced 
in a particular way and it is important to understand which aspects of management are 
important to the caregiver.  Medical and social supports play major roles in the coping 
behaviour of caregivers.  Interaction with the healthcare team in particular, is welcomed.  
Caregivers want to be informed and involved in treatment decisions.  And their involvement 
in the decision making process can affect adherence to treatment119.  Feedback using the 
CLCF-Q was welcomed by all caregivers143.  The feedback not only identified issues 
concerning the caregiver but also served as an educational tool.  The educational needs of 
caregivers should be considered particularly when considering changes in treatment.  Kettler 
et al describes how knowledge of the disease and its management affects adherence to 
treatment144 145 The process of completing the questionnaire as a standalone intervention, 
also served as a good self feedback tool. 
The process of caring for a child with CF is both physically and mentally demanding and can 
be overwhelming, particularly following diagnosis111.  The BOC and the responsibility 
placed on the primary caregiver can cause varying amounts of stress and anxiety and can 
lead to depression119.  This responsibility of caring for a child with CF and the uncertainty of 
disease progression can affect the outlook of the caregiver and the family unit64.  Coping 
behaviours play an important role in the management of challenges and in mediating stress 
levels111.  Whilst improving coping behaviour is beyond the scope of hospital intervention, 
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SE has gained recognition as an important component of coping behaviour102.   SE is 
sensitive to the introduction of minor interventions and can improve coping abilities146.  
Influencing SE from an outpatient setting can be a useful intervention for the caregiver and 
the family.  Studies reveal that coping behaviour is most positively influenced following 
interventions which enable individuals to understand challenging situations111.  Interventions 
should focus on informing participants how to manage stressful situations.  Providing 
feedback on current behaviour and administrating a PROM is an ideal example of this.  It is 
a form of both performance accomplishments and verbal persuasion102. 
Data in this study support the administration of the PROM, the CLCF-Q during the annual 
assessment.  It is feasible and of benefit to routinely integrate the CLCF-Q into the annual 
assessment process.  Furthermore, the initial data support the theory that this integration may 
improve the SE of caregivers.  This improvement in SE could lead to an increased QOL.   
Baseline SE ranged from 26/40 – 39/40 using only validated items and 36/56 – 53/56 
including non-validated items.  Average change in SE was -0.1 in the control group and +1.3 
in the intervention group.  With the inclusion of the non-validated items average increase in 
SE was +0.8 in the control group and +4.2 in the intervention group.   The control group 
showed consistent improvement in 4 items and decline in 3 items.  In comparison the 
intervention group showed consistent improvement in 8 items and a decline in only 1 item.  
The CFSE-Q equates changes in personal confidence, efforts employed, confrontation 
strength and support available.  Firm changes in personal confidence, perceived support, 
efforts employed, problem solving, feeling appreciated and facing challenges were evident in 
the intervention group.   
As suggested, in this study, 94.4% of caregivers were female and 94.4% did not receive 
support with care83.  Ninety percent of caregivers cared for 2 or more children at home.  
Childhood chronic diseases impact on the wider family including siblings and 30% of 
families handled the challenges of living with CF with great difficulty.  Forty percent of 
these families admitted to struggling financially147.  Family and friends offer vital support 
networks to caregivers in addition to the CF team.  Nevertheless, most responsibility remains 
with the primary caregiver and this affects 70% of caregivers greatly.  There is a 
characteristic balance between hopes and worries in caregivers.  Short term hopes remains 
high and unaffected whilst long term worries increase with disease progression. 
Feedback data from all caregivers in the intervention group and the interview shows that 
caregivers uniformly welcomed the study as an intervention to help improve their SE.  The 
qualitative data supported this and established that whilst at home as the primary caregiver 
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they are expected to uphold the burden, they do also require considerable attention 
themselves.  The role of caring for a child is both emotionally and mentally disconcerting.  
Caregivers may also have co-morbidities themselves.  Whilst they normalise their ADL to 
include any additional demands when asked to break down their capabilities and self beliefs 
they are able to do so.   
It is important to recognise that the interpretation of what defines a challenge varies greatly 
both for the caregiver themselves and between caregivers, thus supporting the need for 
qualitative data in this study.  Broad approaches to challenges can be mapped.  Important 
aspects of this approach include family support, CF team support and accessibility, caregiver 
involvement in management decisions and rapport between the caregiver and the clinician.  
Support from the CF team is of particular importance and increases caregiver involvement in 
the decision making process.  The current system in place for communication revolves 
around set clinic appointments.  Whilst the telephone service is available around the clock, it 
relies heavily on the caregiver recognising a weakness and asking for help.  The CLCF-Q 
identifies issues which may not necessarily be recognised as challenges and may otherwise 
be left unidentified.  The annual assessment process is an essential element in monitoring 
disease states and consequent shaping of management.  By improving caregiver-clinician 
communication the CLCF-Q builds on the results available to inform future decisions.  It 
helps emphasise the importance of, “we,” in the decision making process. 
CF care has undergone a rapid change whereby the optimum environment of care is now the 
home.  The benefits of being cared for at home are evident and its value to the caregivers is 
clear138.  To maintain a good level of care, communication between the family and the CF 
team must be maintained.  This involves three key principles; increasing caregiver 
involvement, listening to caregivers and giving regular feedback.  The CLCF-Q works on all 
three principles. 
The basic design of the study was informed following a 3 month period of shadowing annual 
assessments and outpatient clinics to ensure the careful and efficient integration of the 
CLCF-Q.  Study phases were timed to match appointment schedules.  The study 
commitments required from participants were limited to waiting periods in appointments and 
as a consequence all questionnaires and feedback were completed and delivered whilst 
waiting to see members of the healthcare team.  This non-demanding study design 
contributed to the high response rate.  The response rate was initially 100% but later fell to 
85.7% due to cancellations in appointments.  Non-response bias was deemed low as the drop 
in uptake was due to cancellation and not the nature of the study. 
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Despite the successful response rate the total numbers are low due to the restrictions of the 
study design.  Phase 1 of the study centres around the patient’s annual assessment 
appointment, which is individual to the patient.  Phase 2 relies on the individuals successive 
appointments at the outpatient clinic.  These are also flexible.  Thus the duration and timing 
of each phase is unique to the patient concerned.  The relatively few results of the study at 
this early stage, though favourable to the hypothesis, are insignificant for statistical analyses.  
All results have been reported descriptively.  Following the collection of the remainder of the 
data for the pilot phase all results will be graphed to determine distribution type and analysed 
statistically for both minimal clinical and statistical difference.  Power calculations will also 
be carried out to inform sample size for the larger study.   
Descriptively all results except one outlier support the hypothesis showing an increase in SE 
post intervention.  This outlier was only apparent on addition of the non-validated items in 
the CFSE-Q.  The baseline CFSE-Q score was 53/56 and 52/56 post-intervention.  The 
baseline score including validated items only was 39/40 and there was no change in phase 2.  
This study has illustrated that SE is subject to sensitive change.  It is reasonable to assume 
that individuals who hold particularly high levels of SE benefit little from such interventions.  
The high baseline SE score in this case may be the cause of the outlier.  Further data are 
required to verify the merit of this outlier.   
Limitations 
The staggered timeline of the study was shaped around each participants pre-dated 
appointments schedule.  This affected both quantitative and qualitative aspects of the study 
making it difficult to collate results at any one time point.   
Thus an obvious limitation of this dataset is the modest sample size.  Despite an 85.7% final 
recruitment rate the complete dataset only encompasses results from 9 caregivers; though 
partial datasets are available for 18 caregivers.  This thesis does not mark the end of the 
preliminary data collection, however.  The complete set of preliminary data will not only 
allow sample size predictions for a larger study, it will also inform study design.   
Whilst the unique study timeline aided recruitment and compliance it may also adversely 
affect the results.  The time lapse between the intervention and contact with the researcher, 
and the measurements of endpoint SE was sometimes relatively broad, differing from case to 
case; the possibility of interviewer effect at the endpoint must therefore be considered.  As 
demonstrated, SE can be sensitive to slight interventions including interactions.  To maintain 
consistency this bias cannot be removed from the study design.  Further results are required 
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to judge the merit of the change in SE.  Qualitative data will aid this.  If an interviewer effect 
is evident the method of administering the CLCF-Q may need to be adjusted. 
This staggered timeline also relied on the flexibility of the researchers as appointments were 
often rescheduled, cancelled or postponed at short notice.  The drop in final response rate 
was solely due to appointments being rescheduled.  The difficulties of performing such a 
flexible study are currently outweighed by the benefits of compliance but will require 
reviewing when the large scale multicentre study is performed. 
Though the study yielded high recruitment, due to the lack of commitment required outside 
of hospital appointments, one participant raised the issue of privacy. 
“Completing forms in clinic is fine, one problem is my son curious about the answers.  I am 
very open and honest with him about his treatment.  However, I don’t like him to see if I have 
any worries, as he has enough to deal with.  I could tell him not to read what I am filling in, 
but this would increase his anxieties and I don’t like to tell him to go away.” 
Separating the caregiver from their child in a clinic environment is difficult particularly in 
the waiting areas, which is where the majority of questionnaires were completed.  A possible 
solution would be to allow caregivers protected time outside of clinic time though; this may 
increase the commitment required, affecting response rate.  This was attempted by Dyer et al 
but led to poor recruitment and compliance96. 
Several other issues have arisen from the pilot phase.  Baseline SE varies greatly amongst 
caregivers.  External influences are most effective when baseline SE is low102.  A possible 
direction in the study could involve introducing a requirement for low baseline SE in the 
inclusion criteria.  As previously mentioned, those with a high baseline SE are most difficult 
to motivate and show the least improvement following intervention.  This study may not help 
this group of participants at all.  Furthermore, the concept of overconfidence must also be 
considered.  High levels of SE can have negative effects on behaviour.  The second phase of 
the study, can last up to 3 months as it relies solely on the child’s appointment schedule.  
This lengthy period of time may necessitate a greater number of time points between SE 
measurements to improve understanding of external influences on SE. 
Narrative analysis is a slow process making it unsuitable for large amounts of data.  This is 
an indirect limitation on the quantity of qualitative data collectable.  Although the criterion 
for quota sampling only serves as a guide it may further add unnecessary restriction.  
Reproducibility is also difficult with qualitative methods141 148.  Hence, the qualitative data 
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regardless of its validity in the pilot study may not be reflected in the larger study148.  This 
shouldn’t affect the methodology, however.  To increase face value of the data and increase 
representation the larger study should include a larger qualitative sample.   
All of these limitations may have influenced our ability to detect associations between the 
administration of the CLCF-Q and changes in caregiver SE.  They will influence the study 
design and employment of the larger study. 
These findings will add to the growing literature emphasising the role of assessing SE in 
caregivers.  Findings also illustrate a need for assessment and further support for caregivers 
of children with CF.  This is not evident in current research. 
------------------------------ 
Research in the field of CF has transformed significantly from purely quantitative to 
qualitative and now mixed methodology approaches.  Continuity of work in the latter nature 
is welcomed by caregivers and patients.  It substantiates quantitative data.   
“I look forward to taking part in the research as all research with regards to cystic fibrosis 
is extremely welcome!  Thank you.”- (taken from participant feedback) 
5.9. Conclusion 
 
Despite the relatively small sample size, the results of the study to date have shown that SE 
can be assessed and influenced.  Through careful feedback mechanisms aiming to involve 
and empower caregivers in the decision making process regarding the treatment of their 
child, SE can be influenced.  The simple intervention employed in this study was integrated 
into the normal routine of appointments without discord.   
Whilst the results of this study may be used to inform future decisions in relation to 
caregiver-clinician interaction, the ideal result would be for caregivers to utilise self directed 
mastery themselves.  The inclusion of the CLCF-Q into the annual assessment though 
achievable would only be a stepping stone in this process.  SE is subject to sensitive change 
and must be monitored regularly and maintained.  Maintaining SE in all caregivers at the CF 
centre would require considerable commitment.  Ideally, influences on SE must be regulated 
by the caregivers themselves.  Measuring and assessing SE has a place in both research and 
practice where SE measures could reliably show the effect of the intervention on the 
participant111 146. 
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The SE theory needs to be explored further with the family of the child, in particular the 
siblings.  Living with chronic disease can have specific emotional and psychological effects 
on siblings living in the same household.  Paediatric medicine aims for a holistic approach to 
disease management and this includes the family.   
As the child with CF reaches adolescence the role of the primary caregiver diminishes and 
the burden of care lessens.  The burden on the patient however inversely increases as they 
are expected to take responsibility of their own care.  At this transitional stage the SE of the 
patient is important to understand.  Improving SE at this level would be beneficial.  Turner et 
al in Australia working under eHealth Services Research Group are currently aiming to do 
this in a similar manner using information technology as a tool.  There is no published data 
available to date.  Promoting self-management and self-efficacy amongst adolescents with 
CF would be a natural progression from this study116.  
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